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 Brain machine interfaces have the potential to connect patients living with paralysis 
to prosthetics and devices, dramatically improving quality of life[1]–[3]. Intracortical 
electrodes provide the electrode-tissue interface and record action potentials from neurons. 
Over time, the strength of the recorded action potentials diminishes, making repeat trials 
and device control difficult[4]–[6]. The biological cause was believed to be the formation 
of the astroglial scar physically separating the neurons from the recording sites[7], [8]. 
Local neurodegeneration was then identified at the electrode interface[9], and a new theory 
emerged suggesting that a leaky blood-brain barrier (BBB) leads to neurodegeneration[10], 
[11]. A negative correlation was found between recording performance and BBB breach in 
different implanted electrode types[12]. This work led to the questions of what impact 
could therapeutic modulation of the BBB have on electrophysiological function, and what 
mechanisms regulate the BBB in an intracortical electrode implant model? 
 Here we administered a therapeutic inhibitor to modulate the BBB in an electrode 
implant model, while evaluating the functional electrophysiology. We also sought to better 
understand the molecular cues in the electrode implant model and correlated 
electrophysiology and mRNA at a chronic time point. Specifically, the CCL2/CCR2 
pathway was inhibited to prevent pro-inflammatory monocytes recruitment to the electrode 
interface and to also modulate the BBB[13]. Functional Michigan electrodes were 
implanted for 2 and 12 weeks and administered a CCR2 antagonist. The number of animals 
with active recording electrodes was increased at 12 weeks when compared to controls, 
and histological outcomes were improved at 2 weeks in the treatment group. Then, in a 
 xvii 
chronic (>12 weeks) microwire model, mechanisms regulating the BBB, 
neuroinflammation, leukocyte infiltration, and inflammation were analyzed at 1 and 14 
weeks. A significant correlation was found between SNR and PDGFR-β expression, 
suggesting a potential pathway to regulate for improved recording performance. 
 The significance of this work is the increased understanding of the biological 
mechanisms at play in an intracortical electrode implant model. Additionally, these 
mechanisms have been correlated with electrophysiology, assessing functionality. Future 
work would include delving into the temporal aspects of the CCL2/CCR2 pathway, as well 
as exploring the effects of PDGFR-β. MMP-9, and MMP-2 knock models on 
electrophysiology. Alternatively, from a device design perspective, the presence of an 
external connector suggests that the meninges (a part of the BBB) may never heal. 
Removing the connector and creating wireless recording electrodes will be the next 
generation of neural interfaces. Evaluation of this device design in vivo will further 








Neural interfacing to regulate and replace lost sensory and motor abilities is now 
entering clinical trials[2], [3], [6]. Guaranteeing reliable, chronic neural interfacing is 
critical for the success of BMIs. There are ~5.4 million people estimated to be living with 
some form of paralysis in the United States, and the primary causes are stroke, spinal cord 
injury, and multiple sclerosis[14]. BMIs provide the opportunity to improve quality of life 
for these populations by allowing brain connection to a computer or a robotic 
prosthetic[15], [16]. Additionally, BMIs can bypass the damaged neural circuits to 
reanimate paralyzed arms[2], [3] and legs[17]. Deep brain stimulation is a standard 
therapeutic tool for patients living with Parkinson’s disease and the use of BMIs can 
provide a closed-loop system to adjust stimulation parameters based on neural 
recordings[18]–[21].  
Both pre-clinical and clinical research has shown that action potential strength 
diminishes over time[2], [3], [6], [22]–[24]. Currently, all clinical trials use some form of 
spikes (or that frequency range) as the input data for prosthetic control[2], [3], [5], [6], 
[16]. Therefore, continued strength of action potentials is key for improved device control. 
It has been previously thought that the main biological cause for signal deterioration was 
the development of the astroglial scar which physically separated neurons from the 
recording sites[8], [25], [26]. Neurodegeneration was then identified at the electrode-tissue 
interface at a chronic timepoint (16 weeks), suggesting that the biological cause for signal 
failure was neural death[9]. Blood-brain barrier (BBB) breach was identified at the 
electrode interface[11], [27], and the BBB is a therapeutic target to curb neurodegeneration 
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in several neurodegenerative diseases[28]–[32]. Subsequent work showed a correlation 
between electrode failure and BBB leakage[12].  
The objective of this thesis was to identify and target BBB repair mechanisms in an 
intracortical electrode model and observe the functional outcomes. Acute BBB breach in 
the intracortical electrode model is caused by vasculature injury due to implant insertion. 
As a result, infiltrating leukocytes, plasma proteins, and inflammatory chemokine and 
cytokines are able to enter the brain[33]. Chronically, it is believed that the foreign body 
presence of the electrode keeps inflammation levels elevated, resulting in continued BBB 
leakage[12]. Through this work, a specific pathway (CCL2/CCR2) was targeted to evaluate 
the impact of BBB modulation. Additional BBB mechanisms were also correlated with 
electrode functionality to develop a guide for future studies. 
Specific Aim 1: Explore BBB modulation strategies in Michigan electrodes through 
inhibition of the CCR2 pathway 
Following BBB rupture, circulating leukocytes enter the brain[34]. Pro-
inflammatory monocytes are one of the first responders to an injury. These cells are 
CCR2+, and by blocking this receptor, the injury site can be turned into a more anti-
inflammatory environment[35]–[38]. Additionally, CCR2 is also present on endothelial 
cells and when activated, tight junction proteins are disrupted[39]–[41]. The working 
hypothesis was that infiltrating pro-inflammatory monocytes play a critical role post-
implantation. By antagonizing the CCR2 pathway, pro-inflammatory monocytes would 
be prevented from infiltrating at the electrode-tissue interface. CCR2 antagonism would 
also improve the fidelity of the BBB by maintaining tight junction proteins.  
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The objective for this aim was to systemically inject a CCR2-antagonist in vivo 
and evaluate outcome metrics via histology and electrophysiology. Michigan electrodes 
were implanted for 2 and 12 weeks in the barrel cortex of Sprague Dawley rats. Weekly 
electrophysiological recordings were conducted, and at the specified endpoints, histology 
was performed focusing on neuroinflammation, vasculature, and BBB breach. The 
outcomes of this aim are discussed in 0. 
Specific Aim 2: Identify chronic BBB mechanisms related to performance variability 
in microwires 
Currently, the biological mechanisms influencing chronic electrode performance 
are not well understood. The working hypothesis was that mRNA expression of BBB 
components would correlate with recordings and suggest mechanisms behind animal-to-
animal variability. The objectives for this aim were to evaluate mRNA expression of 
tissue explanted at the electrode interface and correlate these profiles with 
electrophysiology by animal. The selected mRNA was divided into four categories of 
interest: 1) neuroinflammation, 2) blood-brain barrier, 3) leukocyte infiltration, and 4) 
inflammation. Each of these foci are related to either the physical BBB breach or the 
subsequent results of BBB breach. mRNA expression was evaluated at 1 and 14 weeks 
after microwire implantation and compared to chronic electrophysiology collected at 14 




Intracortical electrodes are the biological-to-electronic connection in brain machine 
interfaces (BMIs). Research shows that signal amplitude diminishes over time[2], [4], [5], 
and identifying biological mechanisms for this failure can improve clinical outcomes. 
Chronic neurodegeneration occurs at the tissue electrode interface, and one potential 
biologic cause is disruption of the BBB[12]. By targeting the BBB and modulating this 
system, neural health can potentially be improved, resulting in improved signal strength 
and longevity. This review will delve into details about electrode failure, 
neurodegeneration and the BBB, and identify potential BBB therapeutic targets for the 
intracortical electrode model. 
1.1 Clinical significance of intracortical electrodes 
Three different clinical trials are currently being conducted for neural prosthesis, 
which include BrainGate2, Battelle Memorial Institute, and the University of Pittsburgh. 
All clinical subjects have been implanted with the 10 x 10 Blackrock Microsystems “Utah” 
array, which is the only recording electrodes approved by the FDA for clinical use. It is 
well-understood in the field that the quality of action potentials will degrade over time. For 
BrainGate2, over the course of 500 days, a significant decrease in spike amplitude and 
number of units was observed for two subjects[42]. For Battelle, wavelet power decreased 
for the first 150 days, but stabilized afterwards in one subject[2]. For the University of 
Pittsburgh, reduction in number of single was noted after 21 days in one subject[5]. The 
decrease in signal strength heavily impacts the pre-processing methodology. Therefore, 
many have suggested that the algorithms cannot rely on spikes alone and must also use 
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local field potentials (LFPs). The three clinical groups each have their own strategy for 
managing the neural signals, which will be reviewed here. 
Currently, BrainGate2 has the longest running clinical trial for intracortical 
electrodes, with one of their patients having been implanted with Blackrock arrays for over 
1000 days with successful recordings[43]. Between two patients, only 23% of electrodes 
recorded spike activity post 500 days implantation. However, for one patient, ~70% of 
electrodes were recording local field potentials (LFPs) while for the other patient, only 
30% of electrodes were recording LFPs[42]. Power spectrum analysis of LFPs focuses on 
four brain wave frequency categories: 1) delta (0.5 – 3 Hz), 2) theta (3.5 – 7 Hz), 3) alpha 
(8 – 13 Hz), and 4) gamma (30 – 70 Hz)[44]. The BrainGate2 group was interested in high 
frequency LFPs, and added two more frequency categories of interest: 5) high gamma (70 
– 200 Hz) and epsilon (200 to 400 Hz)[42]. In future algorithms, spikes and high-frequency 
LFPs (250 to 2500 Hz) were used for motor decoding[3]. BrainGate2 has conducted studies 
to control a computer mouse in a 2 dimensional space[4], [15], [42], [43], [45], a robotic 
arm with 7 degrees of freedom[16], and most recently controlling functional electrode 
stimulation (FES) electrodes implanted into the patient’s paralyzed arm[46], [47]. 
Battelle tested a patient implanted with a Blackrock Microsystems array for 15 
months (~450 days), and the signals from the array were used to stimulate external FES 
electrodes on the paralyzed patient’s arm to control movement and grasp with 6 degrees of 
freedom[2]. A previous non-human primate study acknowledged the steady decline of SNR 
and number of units over the course of 200 days. A 11-level wavelet analysis was used 
over spikes for the decoding, and the wavelets fell into three categories: 1) LFP (0 to 200 
Hz), 2) multi-units (300 Hz to 1 kHz), and 3) single units (>1 kHz)[24]. The 4 wavelets in 
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the multi-unit frequency were selected for use in the decoder during the clinical trials[2], 
[46]. Wavelets in the multi-unit frequency were selected as they did not significantly 
correlate with the decline in single unit amplitude[24]. 
The University of Pittsburgh demonstrated a subject’s control of a robotic arm with 
7-degrees of freedom over a 13 week time period following implantation of two Blackrock 
arrays[5]. Firing rates from single and multi-units were inputted into the neural 
decoders[5], [6]. The most recent study compared 2 subjects (both with two implanted 
Blackrock arrays) controlling a robotic arm with 7-degrees of freedom with shared control 
by vision-guided robotic assistance. Both subjects were more successful at completing 
reaching, grasp, and object selection tasks[6]. This group has also shown efficacy of 
microstimulation in the somatosensory cortex to elicit tactile sensation[1]. Closed-loop 
tactile sensations are critical for improving reach and grasp tasks[48]–[50]. 
In these trials, the neural signals that are inputted into the decoders for prosthesis 
control provide guidelines for pre-clinical electrophysiological research. No clear 
consensus has been made as to whether spikes or LFPs are the preferred input signal. It is 
also important to remember that these studies are extremely underpowered (n = 1 or 2), so 
more subjects are needed before a path forward can be determined. Interestingly, it appears 
that the traditional LFP range (0 to 200 Hz) does not appear sufficient. Both the BrainGate2 
and the Battelle group have selected frequencies (<250 Hz) that correspond with spiking 
activity[2], [3], [46]. To supplement poor signal recording, improvements in decoders[4] 
and implementation of decoder and neural adaptation algorithms[51] have been proposed, 
and additional assistance from vision-guided robotics have been successfully used[6]. 
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Regardless, improvement in the strength and fidelity of action potentials over the course of 
months (and years) would greatly benefit clinical trials. 
1.2 Chronic intracortical electrode recording failure 
As mentioned in the previous section, a reduction in signal amplitude over time has 
been observed clinically[2], [4], [5]. Additionally, chronic electrode failure has been well 
documented in pre-clinical models[12], [22]–[24], [52]–[54]. A study using Utah 
electrodes in a monkey reported a steady decrease in SNR starting at day 31 until day 
227[24]. Utah electrodes were implanted into the cerebral cortex of 4 cats, and a decrease 
in signal amplitude was observed at 60 days and then again at 200 days[53]. A separate 
study focused on the electrophysiological and histological effects of Utah electrodes at 12 
weeks in rats. Out of 10 implanted rats, only 2 had action potentials and discernable units 
at 12 weeks[52]. In rats, functional electrophysiology was compared across implanted 
Michigan, Utah, and microwire electrodes for 12 weeks. Microwires outperformed both 
Michigan and Utah electrodes in terms of SNR, but all SNRs had reduced by 12 weeks[22]. 
Table 1 – Overview of specs for recording electrodes used in research 
Electrode 
Type













thk: 15 or 50 µm













Ø = 75 µm Cylinder 16 to 32
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Chronic recordings conducted in mice using Michigan electrodes also saw a decrease in 
SNR after 1 month[23].  
 Material – electrode failure 
It is important to acknowledge that different intracortical electrodes are used 
throughout the literature. As seen in Table 1, the most commonly used electrodes are 
microwires, Michigan electrodes (NeuroNexus, MI), Utah electrodes (Blackrock 
Microsystems, UT), and tethered microwires (Microprobes, MD). Utah electrodes are the 
intracortical electrode that has received FDA approval and are therefore the only electrode 
used in clinical trials[43]. Electrophysiology is the standard in vivo measurement for 
function, however, in addition to material and mechanical damage, the cellular 
environment impacts this measurement as well. 
Compromised insulation and damaged recording sites have been observed on TDT 
microwires[55], Microprobes floating microwires[56], NeuroNexus “Michigan” 
probes[57], and BlackRock Microsystems “Utah” needle electrodes[54], [58] following 
chronic in vivo implantation, as well as through accelerated failure lab bench testing[59]. 
This damage leads to increased impedance and non-functioning electrodes. SNR will be 
the highest within the first 2 weeks of implantation (particularly on the day of surgery) 
followed by a steady decline and eventual plateau[12], [22]–[24], [60]. Therefore, the 
impact of compromised insulation and recording site degradation should be taken into 
consideration.   
The type of damage the electrodes encounter is design related. The electrodes fall 
into two categories, NeuroNexus probes and protruding electrodes. For the protruding 
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electrodes, which are Microprobes, Blackrock Microsystems, and TDT, the electrodes 
consist of an inductive material (platinum iridium, platinum-coated silicon, and gold-
coated tungsten) coated with insulation (parylene-C, parylene-C, and polyimide) and a 
single recording site exposed at the distal end of the electrode. The failure points are at the 
electrode sites and in the insulation. For the electrode sites, insulation can delaminate, 
extending the recording site surface area, and damage can occur to the recording site in the 
form of cracks, corrosion, and deformation. Insulation can be compromised be 
delamination and fissures[54]–[56], [58], [59]. 
 NeuroNexus probes have a different design with multiple insulated traces feeding 
into multiple recording sites on a single shank. The electrodes are fabricated from silicon 
and the recording sites are coated in iridium and the insulation on the traces is silicon 
nitride. Kozai et al. demonstrated how mechanical strain can lead to device deterioration. 
The NeuroNexus probes have the traces running under the sputtered iridium (which is 
larger than the recording site). Kozai used an FEM to show the increase in strain at the 
traces at the iridium interface and replicated this result with SEM images from chronically 
implanted electrodes that had increased insulation degradation at the trace-iridium 
interface. Additionally, electrodes that ceased to record had insulation degradation either 
in the vicinity of the recording site or further up the electrode at one of these interfaces. 
For the recording sites, the main issue with the NeuroNexus probes is cracking and 
corrosion of the iridium. For the traces, it is severe cracking in the insulation[57]. 
 Biomechanical – micromotion 
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A study revealed that micromotion at the electrode interface the day of implantation 
is caused by respiration (6–11 µm) and heart beat (2–4 µm)[61]. While this effect is 
reduced by 8 weeks, micromotion is still present[62]. Most notably, this micromotion is 
observed in an anesthetized, stereotaxed animal and does not include micromotion from 
active movement or from plugging in the electrophysiology connectors. Modeling work 
has also shown the impact of strain on the surrounding tissue and the electrode itself[57], 
[63], [64].  
To reduce the biological effects of micromotion, significantly “softer” electrodes 
have been developed and have been shown to reduce the chronic biological response at the 
electrode interface[65]–[73]. A caveat to flexible electrodes is that they are difficult to 
insert into the brain. This has also resulted in a field designing coatings and material 
strategies for easy insertion[68], [74], [75]. An alternate approach is to miniaturize the 
electrodes. Karumbaiah et al demonstrated a reduced immune response using smaller 
NeuroNexus probes (thickness = 15 µm) compared to thicker NeuroNexus probes 
(thickness = 50 µm) of the same length and width[22]. Kozai et al. fabricated carbon 
nanofibers for functional recordings and demonstrated in vivo proof-of-concept for 
electrophysiology and reduced immune response when compared to NeuroNexus 
probes[69]. 
Tethered electrodes are another strategy to reduce the effects of micromotion. By 
tethering, the electrodes can move with the brain and therefore reduce inflammation. 
However, these tethered electrodes are not truly “free floating” as forces are still exerted 
from the ribbon cable which is dental cemented to the skull at an alternate location. 
Previous work has shown that tethered electrodes induce an increased neuroinflammation 
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response when compared to untethered, fixed electrodes of the same material and 
dimensions[22].  
 Biological – cellular milieu  
Following electrode insertion, within 100 microns of the electrode-tissue interface, 
astrocytes and microglia are highly activated. During the acute timeframe (between 
implantation and two weeks post-implantation), reactive astrocytes and reactive microglia 
are heavily recruited to the implant sight, and significant neuronal loss occurs as well [11]. 
Reactive microglia levels peak at two weeks. In the post-acute window (between two and 
eight weeks post-implantation), reactive astrocyte recruitment peaks and then plateaus, 
while reactive microglia decrease. It is important to note that while there is a reduction in 
activated microglia, astrocytes still remain in a more elevated reactive state. During the 
post-acute phase, the neural population remains stable[25], [26]. At chronic time points 
(from eight to sixteen weeks post-implantation), while reactive astrocyte and microglia 
levels remain stable, significant neurodegeneration is observed[11], [76]. The main biotic 
theory for failure is electrode encapsulation by the astroglial scar, which physically 
distances the electrodes from the neurons. However, as the astroglial scar stabilizes within 
the first 4 weeks[11], the data suggests that an alternative cascade is set in motion at 8 
weeks to incite neurodegeneration. 
Experiments revealed the presence of IgG at the electrode interface at acute and 
chronic timepoints[11], [27]. More recently, BBB disruption has been identified as a 
potential cause for neurodegeneration and reduction in recording quality. Research in the 
Bellamkonda lab showed significantly different SNRs between animals implanted with 
 12 
microwires versus animals implanted with Michigan electrodes. Further histology revealed 
that there was less IgG expression at the interface of the microwire animals (better SNR 
performance) while the Michigan electrodes (worse SNR performance) had significantly 
increased IgG expression[12]. Tresco’s lab furthered this result by comparing IgG 
expression of inner electrodes (worse SNR performance) to outer electrodes (better SNR 
performance) within each Utah electrode array. The results showed that electrodes with 
better SNR had reduced IgG expression and visa versa[52]. 
1.3 The blood-brain barrier and neurodegeneration 
 Physiology of the blood-brain barrier 
Surrounding the brain is the meninges which contains cerebrospinal fluid and is 
divided into three layers: the dura, the arachnoid, and the pia. As seen in Figure 1A, 
vasculature runs through these layers in a series of venules and arterioles that penetrate into 
the brain and divide into microvessels[77], [78]. The BBB is a critical organ in the 
regulation of homeostasis in the brain and is responsible for immune surveillance, 
 
Figure 1 – (A) View of vasculature within the brain, including the meninges, which 
is compromised of the dura, arachnoid, and pia layers. (B) Cross section of brain 
vasculature including endothelial cells connected by tight junction proteins, basal 
lamina, pericytes, and astrocyte end feet. (C) Illustration of cell-to-cell junctions 
including tight and adherens junctions. Adapted from [29]. 
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molecular trafficking, and ionic regulation. The BBB is composed of several cellular layers 
(see Figure 1B), which include endothelial cells, pericytes, basal lamina, and astrocyte 
endfeet[29], [79].  
Connecting the endothelial cells are a unique set of tight junction proteins, which 
can be divided into transmembrane (claudins, occludins, junctional adhesion molecules) 
and intramembrane (zonola occludens) proteins. As seen in Figure 1C, zonola occludens 
(ZOs) anchor the transmembrane proteins to the cytoskeleton in the endothelial cell. 
Adheren junctions are responsible for direct endothelial-endothelial linking and include 
PECAM and VE-cadherin proteins[29], [79], [80]. Pericytes, which are imbedded within 
the basal lamina, control blood flow and directly connect with endothelial cells to maintain 
 
Figure 2 – Illustration of BBB disruption caused by injury and/or disease (pink) 
which leads to breakdown of the cellular and protein components of the BBB 
(magenta). This leads to leukocyte, protein, and cytokine infiltration (light blue). 
These causes of BBB breach can create a positive feedback loop, creating 
additional disruption. The result of continued BBB breach is neuroinflammation 
and neurodegeneration (blue). 
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vasculature health and promote angiogenesis[81], [82]. The basal lamina is composed of 
several basement membrane proteins, including collagen IV and laminin[79]. The astrocyte 
endfeet also regulate blood flow and directly connect neurons with vasculature[83]. When 
there is disruption at any of these layers, the neural health of the brain is severely 
compromised[29]. 
 Blood-brain barrier disruption and neurodegeneration 
Each of the cellular and protein components of the BBB are a potential source for 
failure. First and foremost, injury can perturb and rupture blood vessels which directly 
leads to a compromised BBB. More subtly, loss of each layer leads to BBB leakage, 
including tight and adherens junctions[84], pericytes, basal lamina[85], and astrocytes. The 
effects of a disrupted BBB include leukocyte infiltration[81], macromolecule deposition, 
neuroinflammation, and neurodegeneration (See Figure 2).  
Specific examples can be found throughout different neurodegenerative 
pathophysiology (Figure 3). Recent work from the Akassaglou lab delved into the 
mechanism behind demyelination in multiple sclerosis using an EAE model. They 
demonstrated that fibrinogen leakage into the brain activated microglia, which in turn 
phagocytosed the myelin of nearby axons[31], [32], [86]. In an Alzheimer’s disease model, 
pericyte loss led to increased BBB leakage and early neuronal loss[87]. A compromised 
BBB can lead to epilepsy by the uptake of albumin via astrocytes, causing excitotoxicity 
in surrounding neurons[88]–[91]. Work in stroke models have shown how an increase in 
matrix metalloproteinases degrades tight junctions and worsens infarct size[92]. 
1.4 Blood-brain barrier modulation in an intracortical electrode model 
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With mounting evidence suggesting that the BBB is a therapeutic target for 
intracortical implants, the next question is how do we target the BBB? Thus far, reactive 
oxygen species, general inflammation, and pro-inflammatory monocytes have been 
targeted. The Capadona lab has explored anti-oxidants to reduce reactive oxygen species 
at the tissue-electrode interface thought two different compounds, curcumin and 
resveratrol. Both curcumin and resveratrol have shown success in repairing the BBB and 
reducing neurodegeneration in stroke, Alzhemier’s, multiple sclerosis, Parkinson’s, and 
spinal cord injury[93]–[100]. Curcumin and resveratrol controlled release hydrogel 
coatings were developed for Michigan electrodes. These coatings both reduced the immune 
response at 2 weeks, but not at 16 weeks around single shank Michigan electrodes 
implanted in rats[101], [102]. Next, a systemic daily injection of resveratrol was analyzed 
for implanted single shank Michigan electrodes in rats, but again while there was a reduced 
immune response at 2 weeks, this effect was not sustained at 16 weeks[103]. 
 
Figure 3 – Illustrative figure demonstrating neurodegenerative diseases that have 
BBB breach that causes neurodegeneration. 
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Kozai et al explored inhibiting a general inflammation marker, caspase-1, which 
has shown promise in stroke, traumatic brain injury, Huntington's, and Amyotrophic 
Lateral Sclerosis[104]–[108]. Functional single-shank Michigan electrodes were implanted 
into a caspase-1 knockout mouse model. Improved single unit and SNRs were seen in the 
caspase-1 knockout mice compared to wildtype controls[60]. For a more specific look at 
inflammation, Kyriakides’ lab used a CCL2 knockout mouse model to analyze the impact 
of preventing recruitment of pro-inflammatory monocytes in a single shank Michigan 
electrode implant model. At 8 weeks, knockout mice had reduced GFAP and albumin 
expression with increased NeuN expression. qRT-PCR showed a shift towards an anti-
inflammatory profile at 2 weeks[13]. A final study examined the impact the 
neuroprotective and anti-inflammatory effects of minocycline on a microwire electrode 
implant model in rats. At 4 weeks, improved SNRs were observed in minocycline treated 
rats compared to control. GFAP activation was reduced at 1 week in minocycline treated 
rats, but not at 4 weeks[109]. 
For this work, two mechanisms have been proposed. The first, imatinib, is novel 
for application to the electrode implant model. Imatinib targets various aspects of the 
vasculature and wound healing and has shown promise in various neurodegenerative 
disease models. The second, RS 102895, is a CCR2-antagonist used in the Kyriakides’ lab 
work. As no functional analysis was conducted in that work, the implementation of the 
CCR2-antagonist with a functional electrode implant model is the logical next step. 
 Imatinib: Restoring the BBB through vasculature modulation 
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Imatinib mesylate, an FDA-approved tyrosine kinase inhibitor (aka Gleevec), was 
originally developed to inhibit the mutated BCR-ABL in chronic myelogenous leukemia. 
Further research has revealed that imatinib also inhibits c-KIT, which is upregulated in 
gastrointestinal stromal tumors, and platelet-derived growth factor receptors (PDGFRs). 
Imatinib has proven usual at attenuating symptoms in several disease categories, including 
fibrosis, hypertension, and most recently neurodegeneration. 
More importantly, imatinib administration in several neurodegenerative models has 
resulted in a reduction in BBB breach. Originally, Su and colleagues were investigating 
the molecular pathway in stroke after the administration of tissue plasminogen activator 
(tPA) and how to prevent the deleterious side effects of tPA. Su et al. validated that tPA 
increased the production of PDGF-CC, and when the receptor (PDGFR-α) was inhibited 
with imatinib, tPA treatment greatly reduced the infarct size and BBB breach in the stroke 
model[110]. Another group used imatinib in a pericyte-deficient mouse model to reduce 
BBB leakage caused by missing pericytes[111]. Imatinib has also proven successful at 
reducing BBB breach in multiple sclerosis[112] and spinal cord injury[113].  
 Astrocytes and PDGFR-α inhibition with imatinib to reduce MMP-9 production 
PDGFR-α are common on astrocyte endfeet (which interact with the BBB) and may 
play a role in the efficacy of imatinib [110]. MMP-9 is associated with BBB disruption and 
astrocytes are the main resident brain cells to produce MMP-9 [114]. Interestingly, Yang 
et al. have recently identified the impact of IL-1ß on the release of MMP-9 from astrocytes 
through the c-Src/PDGFR/PI3K/Akt-dependent Nox/ROS pathways with the transcription 
factors NF-κB and AP-1 [115], [116]. Following this pathway, by administering imatinib, 
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PDGFR would be inhibited, preventing the downstream transcription of MMP-9. Ma et al., 
2011 has investigated the importance of PDGFR-α in an in vivo intracerebral hemorrhage 
model, and administration of imatinib showed a decrease in MMP-9. 
 Pericytes and PDGFR-ß inhibition with imatinib to prevent angiogenesis 
During angiogenesis, endothelial cells secrete PDGF-BB to recruit pericytes, which 
have PDGFR-ß. Two theories have emerged within the tumor literature for the effects of 
targeting pericytes with imatinib or other PDGFR-ß inhibitors: 1) by inhibiting PDGFR-ß, 
angiogenesis is halted [118], [119], which results in less blood vessel leakage [84] or 2) by 
inhibiting PDGFR-ß, pericytes start to apoptose, which leads to reduced vasculature 
stability [120]. Hosaka et al., 2013 conducted an elegant study to investigate the effects 
PDGFR-ß inhibition in tumor models and explain conflicting results from past studies. 
Their hypothesis was that the resident PDGF-BB levels of the tumors would predict the 
efficacy of imatinib on the tumor. By comparing the vasculature of high PDGF-BB tumors 
to low PDGF-BB tumors for both control and imatinib treatment, it was seen that high 
PDGF-BB responded positively to imatinib with less dextran leakage into the subcellular 
space and, interestingly enough, larger pericyte and smaller endothelial cell coverage in 
the imatinib treated tumors. With low PDGF-BB tumors, imatinib increased dextran 
extravasation and minimized both pericyte and endothelial cell coverage. However, despite 
the differences in tumor vessel leakage, imatinib still significantly reduced the tumor size 
of both high and low PDGF-BB tumors [120]. 
Other studies have shown that imatinib does decrease pericyte population, which 
in turn reduces vasculature [121]–[123]. However, comparisons are difficult across the 
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literature as endothelial cell and pericyte markers are predominantly used to evaluate 
functional outcomes, but a marker for BBB or blood vessel leakiness is not cross-correlated 
with these results. Also, when evaluating these studies it is important to keep in mind that 
more blood vessels or more angiogenesis is not necessarily a good thing. The impact of 
angiogenesis after injury or tissue disruption in the brain is not well understood. However, 
the results from Vlahovic et al., 2007 demonstrated that while imatinib reduced vasculature 
coverage in the tumor model, imatinib concurrently reduced newly forming blood vessels 
at a similar rate, suggesting that imatinib was preventing the formation of new blood 
vessels, as opposed to destroying mature blood vessels. 
 Endothelial cells and Abl inhibition with imatinib to improve cell-to-cell contact 
The mechanisms behind imatinib-induced sealing of the BBB are not fully 
understood; however, research from several different disease models have illuminated 
potential pathways. Within endothelial cells, the relationship between Abl inhibition and 
decreased endothelial permeability has been studied. Imatinib inhibition of Abl has been 
shown to strengthen endothelial cell-to-cell VE-cadherin junctions by increasing 
production of Rac1 and Rap1 GTPases [124]. Within endothelial cells, imatinib also 
inhibits Abl-related gene (Arg) which also improves cell-to-cell and cell-to-matrix contacts 
by preventing the disassembly of focal adhesions, as well as increasing production of Rac1 
[125]. Inhibition of Abl with imatinib has also been shown to prevent apoptosis in 
endothelial cells [126], [127]. 
 Targeting monocytes and BBB leakage through the CCR2 pathway 
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Monocyte chemoattractant protein 1 (MCP-1, also known as CCL2) is the 
chemokine that attracts monocyte, and its receptor is CCR2. Monocytes are circulating 
white blood cells that differentiate into macrophages and dendritic cells. CCL2 works with 
MCP-3 (also known as CCL7) to attract monocytes and regulate macrophage function (See 
Figure 4). When a deficiency for CCL2 exists, alternate chemokines, namely MCP-2 and 
MCP-3, are activated and attract monocytes to areas of inflammation[128]. Targeted 
disruption of SCYA2, the gene encoding CCL2, alone interferes with monocyte 
recruitment to inflammatory sites[129]. However, genetic deletion of both CCL2 and 
MCP-3 altogether results in a near inhibition of monocyte mobilization from the bone 
marrow into the blood stream and an inability to recruit monocytes to sites of 
inflammation[129], [130].  
 CCL2/CCR2 in the CNS and brain 
 
Figure 4 – Pictorial representation of CCL2 recruitment of monocytes and CCL2 
activation of tight junction degradation. 
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CCR2 receptors are present on neurons, astrocyte, microglia, and endothelial cells. 
During non-injured conditions, expression of CCR2 remains low. However, following 
injury, astrocyte and microglia CCR2 expression increases. CCL2 is expressed by several 
CNS cells following injury, including astrocytes, microglia, and neurons. To add literal 
insult to injury, infiltrating macrophages produce CCL2 as well, creating a positive 
feedback loop of monocyte recruitment[37].  
Finally, several neurodegenerative diseases express CCR2 and CCL2 upregulation 
at the onset of disease. Autopsied brain tissues of multiple sclerosis (MS) patients have 
increased CCL2 expression[131], [132]. CCR2 and CCL2 KO MS models exhibited 
reduced symptoms and less macrophage recruitment when compared to WT[133], [134]. 
Additional animal work also suggests that instead of initiating onset, CCL2 further 
amplifies disease progression in MS models[135]. Stroke patients have elevated levels of 
CCL2 in their serum and cerebral spinal fluid[136], [137]. CCL2 and CCR2 KO stroke 
models also exhibit reduced infarct volumes and attenuated macrophage recruitment[138], 
[139]. CCL2 and CCR2 have not been studied as thoroughly in the clinical setting for 
traumatic brain injury (TBI), but animal work suggests an acute (order of 12 hours) 
upregulation of CCL2 post injury[37]. CCL2 and CCR2 KO models with induced TBI have 
reduced cavity sizes and macrophage recruitment [140], [141] 
 CCL2/CCR2 and the blood-brain barrier 
CCL2 also affects BBB permeability by altering tight junction proteins[39], [41], 
[142] (See Figure 4). In vitro administration of CCL2 to cultured microvessels depleted 
ZO-1, occludin, and claudin-5[39], [142]. Intracerebral (IC) injection of CCL2 resulted in 
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significant FITC-albumin leakage in the brain in vivo. When IC CCL2 was injected into a 
CCR2 KO mouse, minimal BBB leakage was observed[41]. As a continuation of this work, 
a middle cerebral artery occlusion to model stroke was applied to a CCR2 KO model. The 
CCR2 KO had a significant reduction in infarct volume, as well as a reduction of infiltrating 
cells, including neutrophils and monocytes[138]. 
 Monocyte and macrophage inflammatory classifications 
Monocytes are a part of the innate immune response and have been divided into 
two subsets: 1) M1-like (pro-inflammatory) and 2) M2-like (anti-inflammatory). For 
humans, CD14 and CD16 surface markers identify monocytes (M1-like are CD14+ CD16- 
and M2-like are CD14+ CD16+). Within mice, Ly6C+ monocytes are M1-like and Ly6C- 
are M2-like. With rats, CD43- monocytes are M1-like and CD43+ monocytes are M2-like. 
In all species, M1-like monocytes predominantly have CCR2 surface markers and M2-like 
monocytes only have CX3CR1 surface markers[143]–[145]. 
Table 2 – Murine markers for M1-like and M2-like macrophages 
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Monocytes differentiate into macrophages, which are divided into three subsets as 
shown in Table 2: 1) M1-like (pro-inflammatory), 2) M2a,c-like – wound healing (anti-
inflammatory), and 3) M2b-like – regulatory (pro and anti-inflammatory). M1-like 
macrophages are responsible for phagocytosis and tissue defense following infection and 
injury. They are the first responders and also regulate reactive oxygen species and nitric 
oxide production[144], [146]. Wound healing macrophages, as the name suggests, are 
responsible for tissue repair. M2a cells produce extracellular matrix components and 
orchestrate fibrosis[144], [146]. M2c cells are responsible for debris clearance and pro-
healing[146]. Regulatory macrophages possess both pro and anti-inflammatory 
phenotypes. These cells suppress innate immunity (classically activated macrophages) for 
clearance of apoptotic cells[144], [146].  
 Chronic monocyte/macrophage infiltration at electrode interface 
In this study, a chimera mouse model was created by harvesting bone marrow cells 
from a cyan fluorescent protein (CFP)+ mouse and injecting the cells into an irradiated 
wild type mouse. After 2 weeks, the chimera mice were implanted with single shank 
Michigan electrodes. Interestingly, CFP+ cells were found up to 16 weeks. Further analysis 
revealed a 60% co-localization of IBA-1 and CFP+ cells, concluding that 60% of the 
infiltrating cells were monocytes/macrophages. Within the macrophage/microglia 
population, co-localization of CD68 and CFP+ cells revealed that only 30% of CD68+ cells 
were resident microglia across all for time points, confirming that infiltrating 
monocytes/macrophages dominant the macrophage/microglia response[147].  
 Foreign body response of intracortical electrodes in CCL2 KO model 
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Sawyer et al. proceeded to investigate the effect of CCL2 elimination on the foreign 
body response. Single shank Michigan electrodes were implanted into wild-type and CCL2 
KO mice over the period of 1, 2, and 8 weeks. Histology revealed that neural density 
(NeuN) was increased in the CCL2 KO at 2 and 8 weeks. Astrocyte activation (GFAP) was 
significantly reduced at the 8 week time point as was albumin (MSA). Interestingly, the 
macrophage population (Mac-3) increased at 2 weeks, but not 1 or 8 weeks, but this 
reaction has been reported in other work using CCL2 KO models. Wild-type mice were 
then injected with a CCR2-antagonist, and a significnat increase in NeuN+ cells and a 
significant decrease in Mac-3+ cells was observed[13]. 
Next, mRNA gene data was collected at 2 weeks. A significant upregulation was 
observed in the CCL2 KO mouse for anti-inflammatory markers (CD163, CD206, Arg-1). 
No significant change was seen in the microglia population (CD68). For the two pro-
inflammatory markers, no change was observed for CCR7, while CD80 was significantly 
upregulated in the CCL2 KO mouse[13]. 
1.5 Conclusion 
Chronically implanted intracortical electrodes have been shown to lose signal 
amplitude over time in both clinical[2], [4], [5] and pre-clinical models[22], [24], [53], 
[60]. Many factors, both device and biological, contribute to signal failure. The BBB has 
been identified as a potential biological target to reduce neurodegeneration at the electrode 
interface and improve recordings[9], [11], [12], [27]. Breakdown of the BBB following 
injury is a complicated process. Through this review, two therapeutic strategies have been 
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identified to modulate the BBB: 1) CCR2-antagonism and 2) Imatinib. The following thesis 
will evaluate BBB modulation and the impact on functional recordings. 
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THE IMPACT OF CCR2 ANTAGONISM ON A FUNCTIONAL 
INTRACORTICAL ELECTRODE MODEL 
1.6 Introduction 
Intracortical recording electrodes are a key part of brain computer interface, and  
this technology can allow patients to directly interface with robotics, computers, or their 
own limbs[2], [3], [17], as well as provide closed-loop systems for deep brain 
stimulation[19], [148]. These technological advancements require a chronic functional 
interface, but several studies have demonstrated consistent chronic electrode failure[12], 
[22]–[24], [52], [53]. Previously, the development of the astroglial scar was credited as the 
cause of electrode failure. Neurons need to within 100 µm of the recording sites, and the 
astroglial scar, which develops between the electrode and neural tissue, was thought to 
separate the neurons this distance[8], [25]. However, McConnell et al. demonstrated that 
neurodegeneration is initiated at a chronic timepoint (>8 weeks)[9]. Other work has 
replicated this result[11] and shown that the astroglial scar stabilizes after 8 weeks[9]–[11], 
[149], which suggests an alternate biological mechanism. Winslow et al identified the 
presence of IgG, a macromolecule found in the blood, at the electrode-tissue interface, 
which suggests a breached blood-brain barrier (BBB)[10], [27]. 
BBB disruption has been implicated as the cause of neurodegeneration in several 
neurodegenerative diseases[29], [150]. Saxena et al explored the variations in signal-to-
noise ratios (SNRs) between different electrode types. The results showed that microwires 
had higher SNRs for a longer duration of time when compared to Michigan electrodes. 
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Histological analysis revealed that microwires had significantly less IgG accumulation than 
Michigan electrodes, suggesting a correlation between BBB breach and SNR[12].  
 The objective of this research was to modulate the BBB and observe the impact on 
histology and electrophysiology in an intracortical electrode model. The BBB is composed 
of endothelial cells, tight and adherens junction proteins, pericytes, basal lamina, and 
astrocyte endfeet[29]. Removal or disruption of any of these components leads to BBB 
breach, which is caused by injury or pathology[150]. The results of BBB disruption include 
leukocyte extravasation, macromolecule deposition, and inflammatory cytokine release, 
which can lead to neuroinflammation and eventually neurodegeneration[33], [81], [84]. 
With such a complex system, several modulation strategies exist.  
 CCL2 removal has been shown to reduce the immune response at 8 weeks in an 
intracortical electrode model[13]. The CCL2/CCR2 pathway has been heavily explored in 
terms of pro-inflammatory monocytes and macrophages and has expanded to the CNS[35]–
[38]. The CCR2 receptor is common on pro-inflammatory monocytes that are recruited 
following injury, which then differentiate into pro-inflammatory macrophages. By 
inhibiting the monocyte recruitment (by blocking CCL2 or CCR2), the influx of anti-
inflammatory monocytes to the injury site will create a more anti-inflammatory 
environment[35]–[38]. Leukocyte extravasation is both a cause and effect of BBB 
disruption. CCR2 is also present on endothelial cells and its activation disrupts tight 
junction proteins[39]–[41].  
 The objective of this study was to apply CCR2 inhibition to a functional electrode 
implant model. Daily injections of a CCR2-antagonist were administered to rats implanted 
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with functional Michigan electrodes. Electrodes were implanted in the barrel cortex and 
weekly electrophysiological recordings were conducted. At 2 and 12 weeks, rats were 
euthanized, and histology focused on neuroinflammation and BBB leakage was analyzed.  
1.7 Methods 
 Surgical preparation and electrode implantation 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Georgia Institute of Technology. Adult male Sprague Dawley 
rats (250 – 300 g) were implanted for 2 weeks (non-functional) or 12 weeks (functional). 
Four shank “Michigan” electrodes (NeuroNexus, MI) with a tetrode recording site design 
were purchased for implantation. The electrodes were 3 mm long, 83 µm width and 50 µm 
thick and were spaced 150 µm apart (center-to-center). All electrodes were sterilized by 
ethylene oxide and degassed for 12 hours. Each rat was anesthetized with 2% isoflurane, 
and the head was shaved and sterilized with chlorohexidine and isopropanol. After 
induction, each rat received an intramuscular injection of slow release buprenorphine. Each 
rat’s head was stereotaxtically positioned and a subcutaneous injection of lidocaine was 
administered to top of the head prior to incision. Following a midline incision, the 
periosteum was scraped away, and etch gel (Henry Schein, NY) was applied to the skull. 
Holes for the anchoring screws were then drilled and 5 screws were inserted (1 on the 
opposite side of the craniotomy, 2 anterior to bregma on either side of the midline, and 2 
posterior to lambda on either side of the midline as seen in Figure 5A). A 3 x 5 mm 
craniotomy was drilled at 1.5 mm posterior from bregma and 4 mm lateral to the midline 
(Figure 5A). The dura was retracted using a bent 25-gauge needle and bleeding was 
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controlled using gel foam (Pfizer, NY) soaked with sterile saline. For the functional 
electrodes, grounding wires were wrapped around the anchoring screws prior to insertion. 
Each array was implanted at a 15-degree angle and a depth of 1200 µm, targeting the IV 
cortical layer of the barrel cortex at a rate of 1 mm/min (Figure 5B). Sterile 1.5% SeaKem 
agarose (Lonza, NJ) was applied above the craniotomy and UV curing dental cement 
(Henry Schein, NY) was used to secure the electrodes to the skull and the anchor screws. 
The skin was wound clipped around the connector. After removal from anesthesia, each 
rat received a subcutaneous injection of enrofloxacin (antibiotic) and ketoprofen (anti-
inflammatory), as well as an intraperitoneal injection of either the treatment or vehicle 
control. Animals received daily subcutaneous injections of enrofloxacin for 2 weeks. 
 
Figure 5 – (A) Location of craniotomy to target the barrel cortex, along with the 
location of screws. (B) Michigan electrodes implanted in the brain. (C) Sorted units 
and corresponding (D) filtered recording that has been thresholded. 
 
 30 
 RS 102895 preparation and administration 
Research grade RS 102895 (Santa Cruz, TX) was administered intraperitoneally 
(IP) at a dose of 3 mg/kg/day. RS 102895 was dissolved in dimethyl sulfoxide (DMSO) at 
a 10x concentration and stored at -20°C. The day of injection, RS 102895 was diluted to 
1x using sterile saline. The total injection volume was 1 mL, so that only 10% DMSO was 
injected into the animal. RS 102895 was injected every 20 – 28 hours starting immediately 
after electrode implantation and concluding the day of euthanasia. Control animals 
received daily 1 mL IP injections of the vehicle (10% DMSO in saline, sterile) for the same 
duration.  
 Electrophysiology and analysis 
 
Figure 6 – Example of unit sorting for recording with (A-D) and without (E-H) 
spikes. (A,E) Filtered signal that has been thresholded (red line) at -4σ and 
thresholded waveforms are superimposed above. (B,F) Overlaid waveforms for 
sorted units. (C,G) PCA for sorted units. (D,H) Average waveforms and ISI 
histograms for sorted units. 
 31 
 Weekly recordings were collected with a 32-channel data-acquisition system 
(Plexon, TX). Signals were amplified at 1000x gain, band-pass filtered at 500-5000 Hz and 
sampled at 40 kHz. Animals were anesthetized with ketamine/xylazine/acepromazine 
cocktail as isoflurane suppresses cortical firing in the barrel cortex. For each recording 
session, two files were recorded. The first was an evoked file in which the rat’s whiskers 
were rapidly deflected for ~1 minute, generating action potentials. Peak-to-peak voltages 
(Vp-p) were then calculated from the first file following sorting.  The second file was a noise 
file in which no signals were evoked for 10 seconds. Following removal of spontaneous 
action potentials, the standard deviation of noise was calculated from the second file. The 
purpose of these recordings is to generate action potentials for proof-of-concept testing of 
the CCR2-antagonist model. 
 In Offline Sorter (Plexon, TX), the channels in the evoked files were thresholded 
at -4σ (standard orders of deviation) as seen in Figure 6A,E. Waveforms that crossed the 
threshold were selected (Figure 6B,F), and a PCA plot was generated with a single point 
for each waveform (Figure 6C,G). Units were sorted using K means automatic sorting, 
and these sorted units usually represented multi-units. The interspike interval (ISI) 
histograms were calculated for each unit (Figure 6D,H). Sorted units for every channel 
were manually evaluated. If the unit had fewer than 200 waveforms the unit was excluded 
from analysis. Additionally, if the ISI histogram or waveforms were abnormal, the unit was 
excluded as well. Figure 6A-D shows an example recording with two viable units from an 
electrode at week 1. Figure 6E-H shows the same electrode at week 6. No clear spiking 
activity is observed in Figure 6E. However, waveforms are still detected as crossing the 
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threshold. With the manual exclusion criteria, both units are excluded from analysis for 
having less than 200 waveforms and irregular ISI histograms (Figure 6H). 
 To calculate percentage of active electrodes, active electrodes are determined by 
having at least one viable unit. To calculate percentage of animals with active electrodes, 
an animal is viable as long as there is one active electrode on the recording array. To 
calculate SNR, the sorted files were exported from Plexon into Matlab. Custom code was 
used to calculate the SNR by dividing the peak-to-peak voltage (Vp-p) by 2 times the 
standard deviation of noise, which was recorded from the same electrode in the same 
animal at the same timepoint (Equation 1)[151]–[153]. Prior to calculating the standard 
deviation of noise, any spontaneous action potentials were removed from the noise file. 
Animals that never had evoked or spontaneous signal were excluded from the study.  




 A nested ANOVA model was created to determine significance. As described in 
Equation 2, µ is the grand mean, τ is the effect of time with I as the time index, γ is the 
effect of treatment with j as the treatment index, α is the inter-animal variability with k as 
the index of animals nested with j (treatment), β is inter-electrode variability with l as the 
electrode index nested within k (animals), and ε is error for time, treatment, animals and 
electrodes. 
Equation 2 𝒚𝒊,𝒋,𝒌 = 𝝁 + 𝝉𝒊 + 𝜸𝒋 + 𝜶𝒌(𝒋) + 𝜷𝒍(𝒌) + 𝜺𝒊,𝒋,𝒌,𝒍 
 𝒊 = 𝟏, … , 𝟏𝟐; 𝒋 = 𝟏, … , 𝟐;  𝒌 = 𝟏, … , 𝟒; 𝒍 = 𝟏, … , 𝟒;  
 Tissue preparation, immunohistochemistry, and microscopy 
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Three hours prior to euthanasia, 1 mL of 3% Evans Blue (w/v) in sterile saline was 
intravenously injected into each animal. At 2 and 12 weeks, animals were anesthetized 
with ketamine (50 mg/kg)/xylazine (10 mg/kg) /acepromazine (1.67 mg/kg) and 
transcardially perfused with PBS, 4% paraformaldehyde, and 20% sucrose (200 mL, 
sequentially). The skulls with electrodes still implanted were removed and post-fixed in 
4% paraformaldehyde overnight at 4°C and then transferred to 30% sucrose, overnight at 
4°C. Electrodes were then carefully extracted from the brains, and the brains was stored at 
4°C in 30% sucrose until they sunk to the bottom of the container. Brains were 
cryosectioned at 14 µm thickness in serial on charged glass slides (VWR, PA).  
Please refer to Table 3 for primary and secondary antibodies used. Sectioned slides were 
washed with PBS and blocked with blocking solution (4% goat serum and 0.5% Triton X-
100 in PBS) for 1 hour. The primary antibodies were incubated at 4°C overnight. The slides 
were then washed with PBS and washing solution (0.5% Triton X-100 in PBS), and the 
secondary antibodies were incubated at room temperature for 1 hour. Next, the slides were 
incubated with 4’,6-diamidino-2-phenylindole (DAPI) nuclear stain (Life Technologies, 
Table 3 – Antibody chart for immunohistochemistry 
Primary antibodies Company Catalog #
Rabbit anti-GFAP DAKO M0761
Mouse IgG1 anti-NeuN Millipore MAB377
Mouse IgM anti-EBA Biolegend 836802
Rabbit anti-Collagen IV Abcam ab19808
Secondary antibodies Company Catalog #
Goat anti-mouse IgG1 488 Thermo Fischer Scientific A-21121
Goat anti-rabbit 647 Thermo Fischer Scientific A-21244
Goat anti-mouse IgM 488 Thermo Fischer Scientific A-21042
Goat anti-rat IgG 647 Thermo Fischer Scientific A21247  
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NY) for 15 minutes, followed by several washes of PBS and washing solution. The slides 
were coverslipped with Fluormount-G (Southern Biotech, AL) and left at room 
temperature overnight in the dark. The coverslip was nailpolished to the slides and stored 
at -20°C. For Evans Blue, slides were immediately coverslipped and nailpolished. 
 Quantification and analysis of histology 
Slides were imaged at 10X using the inverted DMI8 microscope (Leica 
Microsystems, IL). Slides from the distal end of the electrode (at the location of the 
recording sites) were used for analysis in FIJI[154]. For IgG and GFAP, a 400 µm x 100 
µm rectangle was centered around each electrode and the intensity profile was calculated. 
The area under the curve was calculated using custom Matlab code and distances were 
binned from 0 to 50 µm, 50 µm to 100 µm, 100 µm to 150 µm, and 150 µm to 200 µm. For 
NeuN, images were thresholded, a 400 µm x 100 µm rectangle was centered around each 
electrode, and cells were counted using particle analysis. For Col IV and EBA, images 
were thresholded, a 400 µm x 100 µm rectangle was centered around each electrode, and 
the percent area was calculated. In addition, at 12 weeks, all thresholded images (NeuN, 
Col IV, and EBA) were binned from 0 to 50 µm, 50 µm to 100 µm, 100 µm to 150 µm, 
and 150 µm to 200 µm on the side of the electrode with the recording sites. The intensity 
analysis for IgG and GFAP were also recalculated using only one side of the electrode. 
To determine significance, a nested ANOVA model was calculated in Matlab. As 
described in Equation 3, µ is the grand mean, τ is the effect of time with i as the time 




Figure 7 – (A) Example of signal loss between 1 and 12 weeks. Comparison of 
control and CCR2-antag treated animals over time for (B) percentage of animals 
with active electrodes (p < 0.05), (C) percentage of active electrodes, and (F) SNR. 
Control has n = 5 and CCR2-antag has n = 4. Individual animal plots for (D,E) 
percentage of active electrodes and (G,H) SNR for CCR2-antag and control. 
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variability with k as the index of animals nested with j (treatment), β is inter-electrode 
variability with l as the electrode index nested within k (animals), and ε is error for time, 
treatment, animals and electrodes. 
Equation 3 𝒚𝒊,𝒋,𝒌 = 𝝁 + 𝝉𝒊 + 𝜸𝒋 + 𝜶𝒋(𝒌) + 𝜷𝒌(𝒍) + 𝜺𝒊,𝒋,𝒌 
 𝒊 = 𝟏, … , 𝟐; 𝒋 = 𝟏, … , 𝟐;  𝒌 = 𝟏, … , 𝟒; 𝒍 = 𝟏, … , 𝟒;  
1.8 Results 
 Electrophysiology 
Following electrode implantation and daily treatment or vehicle administration, 
weekly electrophysiological recordings were conducted from the barrel cortex. Briefly, 
after ketamine anesthetization, a recording of ~10 seconds was taken, which was classified 
as the noise file. Next, an evoked recording was made by deflecting the rat’s whiskers to 
evoke action potentials in the barrel cortex for ~60 seconds. Recorded signals were 
thresholded at -4σ and sorted offline using automatic K means sorting. Units were 
manually validated by excluding units with less than 200 waveforms. Additionally, units 
with abnormal waveforms or abnormal ISI histograms were excluded as well. Percentage 
of active electrodes and percentage of animals with active electrodes were calculated from 
these validated units. SNRs were calculated in custom Matlab software. 
Figure 7A demonstrates an example of action potential loss over time, and this is 
the definition for signal loss. Percentage of animals with active electrodes was calculated 
in Figure 7B. At 12 weeks, each CCR2-antagonist treated rat (n = 4) had active electrodes, 
while only 1 of the control rats had signal (n = 5). Within the control group, rats lost viable 
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signal at 2 weeks (1), 9 weeks (2) and 11 weeks (1). There was a significant difference 
between groups (p < 0.05, two-way ANOVA).  
Percentage of active electrodes was evaluated next (Figure 7C). No significant 
difference was observed between the two groups. However, for both groups, the percentage 
of active electrodes significantly decreased over time (p < 0.05, two-way ANOVA). 
Figure 7E,G show the individual animal plots of percentage of active electrodes for the 
CCR2-antagonist and the control group, subsequently.   
SNR were then calculated across each electrode for each rat at each time point from 
the Vp-p and standard deviation of noise. No significant difference was observed between 
CCR2-antag and control (Figure 7D). Again, there was a significant decrease in SNR over 
time between the two groups (4-way nested ANOVA, p < 0.05). Figure 7F,H show the 
individual animal plots of SNR for the CCR2-antagonist and the control group, 
subsequently. There was significant difference in Vp-p or noise. Vp-p did significantly 
decrease over time. Noise remained constant until 11 weeks, when there was a significant 
increase (data not shown). 
 Histology 
Rats were sacrificed at 2 and 12 weeks via transcardially perfusion with 
paraformaldehyde (n = 4 – 7.) Brains were removed, cryosectioned, and stained with 
antibodies of interest. The focus of the histology was to analyse the neural population, the 
vasculature, and BBB leakage. Slides were imaged at 10x and analysed in FIJI via intensity 
analysis, cell counting, and thresholded percentage area. Four-way nested ANOVAs were 
used to determine significance. 
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 Neural inflammation 
NeuN (neuronal nuclei) is a common antibody to detect the neural population. After 
thresholding the images, a 400 µm x 100 µm rectangle was placed around each electrode 
and cells were counted. At 2 weeks, NeuN expression was significantly greater in CCR2-
antagonist treated animals compared to control (Figure 8A, C, p < 0.05). By 12 weeks, the 
effect had disappeared; there was no difference between treatment and control at 12 weeks, 
and the 12 week control was significantly higher than the 2 week control (Figure 8A, C, p 
< 0.05). Further analysis was conducted on the 12 week samples by restring the region of 
 
Figure 8 – (A) Representative images of NeuN+ neurons for control and CCR2-
antagonist treated tissue at 2 and 12 weeks (Scale bar = 100 µm). (B) Magnified 
view at 12 weeks for control and treated (Scale bar = 50 µm). (C) Cell count for 2 
and 12 week data for CCR2-antagonist and control (* p < 0.05 between treatments, 




interest (ROI) to the side of the electrode with the recording sites, and the 100 x 200 µm 
ROI was binned into 100 x 50 µm sections. The CCR2-antagonist group had significantly 
higher NeuN+ cells in the 0 – 50 µm bin compared to control (Figure 8B, D, p < 0.05). 
However, this effect disappeared in the subsequent bins.   
 GFAP is upregulated in reactive astrocytes and is used to evaluate 
neuroinflammation. A 400 µm x 100 µm rectangle was placed around each electrode and 
the intensity profile was calculated. There was no significant difference at 2 or 12 weeks 
between the control and CCR2-antagonist treated animals. GFAP expression did 
significantly increase between 2 and 12 weeks, which resulted in a localized scar (Figure 
9A, B, p < 0.05). No difference was observed between treatment and control in the binned 
integral of intensity (Figure 9C).  
 
Figure 9 – A) Representative images of GFAP+ astrocytes for control and CCR2-
antagonist treated tissue at 2 and 12 weeks (Scale bar = 100 µm). (B) Percentage+ 
area for 2 and 12 week data for CCR2-antagonist and control (# p < 0.05 between 
time). (C) Binned analysis of GFAP for 12 week data.   
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 Vasculature integrity 
To build upon the antibody markers of the previous section, the health of the 
surrounding vasculature was evaluated. Collagen IV (ColIV) stained for vasculature and 
endothelial barrier antigen (EBA) showed BBB+ vasculature. For both ColIV and EBA, 
images were thresholded and the percent positive area was calculated for a 400 µm x 100 
µm rectangle centered on each electrode. At 2 weeks, there was a significant increase in 
EBA expression in the CCR2-antagonist treated animals compared to control (Figure 10A, 
C, p < 0.05). At 12 weeks, there is no significant difference between treatment and control, 
 
Figure 10 – (A) Representative images of EBA+ vasculature for control and 
treated animals at 2 and 12 weeks. (B) Representative images of ColIV+ 
vasculature for control and treated animals at 2 and 12 weeks. (C) Comparison of 
percentage area of EBA for 2 and 12 weeks (* p < 0.05 between treatment, # p < 
0.05 between time). (D) Binned analysis of EBA for 12 week data. (E) Comparison 
of percentage area of ColIV for 2 and 12 weeks. 
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and there was a significant increase in between the control from 2 to 12 weeks (Figure 
10A, C, p < 0.05). In Figure 10D, for 12 weeks, the ROI was binned in 100 x 50 µm 
sections. From 50 – 100 µm, a significant increase was observed in EBA+ area in CCR2-
antagonist animals compared to control. However, EBA expression stabilized in the 
subsequent between the two groups. No difference was seen at 2 or 12 weeks in ColIV 
expression between treatment and control or over time (Figure 10B, E). 
 BBB breach 
To evaluate BBB breach, IgG was analyzed. IgG is a common protein found in the 
blood. This antibody is used as a BBB breach marker as it does not cross an intact BBB, 
so the presence of this protein denotates leakage. To analyze IgG, a 400 µm x 100 µm 
rectangle was centered around each electrode and the vertical intensity profile was 
calculated. The area under the curve was then calculated for each intensity profile for 
comparison and binned from 0 to 50 µm, 50 to 100 µm, 100 to 150 µm, and 150 to 200 
µm. At 2 weeks, there was no significant difference between treatment but at 12 weeks, the 
CCR2-antagonist had significantly increased (Figure 11A, B, p < 0.05). Figure 11D, F 
show the binned integrated intensity values for 2 and 12 weeks respectively. For 2 weeks, 
CCR2-antagonist was significantly lower for each binned distance, while there was no 
significance at 12 weeks. 
To assess live BBB breach, 1 mL of 3% Evans Blue (w/v) in sterile saline was 
injected 3 hours before euthanasia. Evans Blue binds to albumin, which is a protein found 




Figure 11 – (A) Representative images of IgG+ expression for control and treated animals at 2 and 12 weeks. (B) 
Representative images of Evans Blue+ area for control and treated animals at 12 weeks. (C) Comparison of integrated 
intensity of IgG for 2 and 12 weeks (* p < 0.05 between treatment, # p < 0.05 between time). (D) Binned analysis of IgG for 
12 week data. (E) Binned analysis of Evans Blue for 12 week data. (F) Binned analysis of IgG for 2 week data (* p < 0.05). 
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electrode interface at 12 weeks as seen in Figure 11B, and significantly correlated with 
IgG expression (see supplemental data). However, no differences were observed between 
the treatment and control (Figure 11E). 
1.9 Discussion 
Elucidating the biological failure mechanisms for intracortical electrodes is crucial 
for extending the lifetime of the implanted devices. In this work, the CCL2/CCR2 pathway 
was evaluated in terms of functional electrodes. While no difference was observed with 
SNR, all CCR2-antagonist treated rats still had active electrodes at 12 weeks, which was a 
significant improvement compared to controls. At 2 weeks, CCR2 antagonism increased 
the neural population, reduced BBB leakage, and improved BBB+ vasculature (See Table 
4). At 12 weeks in CCR2-antagonist treated animals, a significant increase occurred in 
NeuN+ cells from 0 – 50 µm. There was also a significant increase in EBA+ vasculature 
from 50 – 100 µm. However, IgG expression in CCR2-antagonist group had significantly 
increased compared to the 2 week counterparts, and was also positive for Evans Blue.  
Table 4 – Overview of changes in antibody expression (++ significant increase, -- 




CCL2 is most commonly used to recruit CCR2+, pro-inflammatory monocytes. 
This pathway has been heavily explored in wound healing[155], [156] and foreign body 
research[157]–[159], and has been extended to neurodegenerative diseases[35], [38]. Use 
of CCL2 KO models have significantly improved outcomes in rodent neurodegenerative 
disease models such as multiple sclerosis[160], [161], Alzheimer’s disease[162], traumatic 
brain injury[140], [141], [163], stroke[164], and epilepsy[165], [166]. CCL2 was secreted 
by microglia cultured from extracted intracortical electrodes[8]. Recent work from the 
Kyriakides’s lab demonstrated the benefits of CCL2 inhibition in an intracortical electrode 
implant model, and the resulting switch an anti-inflammatory environment[13].  
Along with the CCL2 work from the Kyriakides lab[13], others have attempted to 
modulate the immune response in a single Michigan intracortical electrode model. The 
Capadona lab has studied the impact of reactive oxygen species and subsequent modulation 
using curcumin[101] and resveratrol[102], [103]. For both treatments, there were no 
histological differences chronically (16 weeks) when compared to controls. The electrodes 
were not functional, so no electrophysiological measurements could be made. Kozai et al 
implanted functional Michigan electrodes into caspase-1 KO mouse model for 180 
days[60]. Caspase-1 has been linked to inflammation and neurodegeneration in 
neurodegenerative diseases, including stroke. Kozai et al. demonstrated an increase in 
duration of single units for the caspase-1 KO model.  
Chronic local neurodegeneration has been observed at the electrode interface[9], 
[11], and it is reported that neurons need to be within 100 µm of the electrode site in order 
to successfully record action potentials[8], [25], [167]. A significant difference was seen 
in NeuN+ cells within 0 to 50 µm of the electrode interface. While this effect covers a 
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small area, the health of the neurons remains unknown. Fluorojade C, a common marker 
for neurodegeneration, would better elucidate the status of the neurons at the electrode 
interface. 
The blood-brain barrier has been identified as an important target in intracortical 
electrodes[11], [12], [52], [69], [168]. Activation of CCR2 receptors on endothelial cells 
has been shown to reduce tight junction protein expression[39]–[41], [142], [169], and to 
also activate angiogenesis[170]–[172], which leads to leaky vasculature[173]–[175]. At 2 
weeks, electrode implanted animals treated with the CCR2-antagonist had a significant 
reduction in IgG expression and a significant increase in EBA expression compared to 
controls. This data would suggest that CCR2-antagonism decreased BBB leakage and 
improved tight-junction expression acutely. Also at 2 weeks, NeuN+ cells were 
significantly increased in CCR2-antagonist animals compared to control. 
 
Figure 12 – Control at 12 weeks with (A) ColIV (magenta) and EBA (cyan) merged 
and with (B) GFAP (green) and IgG (red) merged. CCR2-antagonist at 12 weeks 
with (A) ColIV (magenta) and EBA (cyan) merged and with (B) GFAP (green) and 
IgG (red) merged. 
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Chronically, the differences were subtler. A significant increase was observed in 
the CCR2-antagonist group for EBA+ vasculature from 50 – 100 µm compared to control 
(Figure 12A, C). This could suggest that the CCR2-antagonist has repaired vasculature 
closer to the electrode-tissue interface. However, IgG expression in CCR2-antagonist rats 
had significantly increased at 12 weeks compared to CCR2-antagonist rats at 2 weeks 
(Figure 12B, D). This data was confirmed by Evans Blue, signifying an active breach. 
Therefore, vasculature has not been completely sealed in the CCR2-antagonist group. 
DMSO, which was used to dissolve the CCR2-antagonist, RS 102895, is known to 
facilitate drug permeability through the BBB[176], [177]. However, these effects have 
been shown to be reversible[178]. Also, IgG leakage was present in control Michigan 
electrodes at 16 weeks post-implantation[12].   
Both biotic and abiotic causes can lead to inflammation and device failure. 
Micromotion is a mechanism that could have led to the increase in IgG expression at 12 
weeks in the CCR2-antagonist treated group (and maintained IgG expression in the control 
group). A study revealed that micromotion at the electrode interface the day of implantation 
is caused by respiration (6–11 µm) and heart beat (2–4 µm)[61]. While this effect is 
reduced by 8 weeks, micromotion is still present[62]. Most notably, this micromotion is 
observed in an anesthetized, stereotaxed animal and does not include macromotion induced 
by active movement or by plugging in the connectors for electrophysiological recording. 
Modeling work has also shown the impact of strain on the surrounding tissue and the 
electrode itself[57], [63], [64]. Additionally, research has demonstrated a reduced immune 
response for electrodes that are not anchored to the skull and are truly free floating (not 
tethered to an off-site connector)[179]–[181].  
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The use of a CCR2-antagonist did reduce animal variability and led to active 
electrodes for all treated rats at 12 weeks (compared to only 1 out of 5 for the control rats). 
The increase of NeuN+ cells from 0 – 50 µm and the increase of EBA+ vasculature from 
50 – 100 µm in CCR2-antagonist treated animals may account for this change. Since the 
histology changes are over a small area, this may explain why no differences were seen in 
SNR, Vp-p, and percentage of active electrodes as these measures may not be sensitive 
enough to delineate these changes. 
1.10 Conclusion 
CCR2-antagonism in an electrode implant model has been shown to significantly 
impact the immune response at an acute time point. Chronically, CCR2-antagonism 
extended the lifetime of implanted electrodes and had a subtle, but significant effect on 
neuroinflammation and the BBB. Interestingly, BBB leakage persisted at 12 weeks in the 
CCR2-antagonist group. Further exploration of abiotic mechanisms such as micromotion 
is necessary to better understand the chronic cause of BBB leakage.  
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CORRELATION OF MRNA EXPRESSION TO ASSESS 
RECORDING VARIABILITY IN A CHRONIC, FUNCTIONAL 
INTRACORTICAL ELECTRODE MODEL 
1.11 Introduction 
Clinical trials for brain machine interfaces (BMIs) using intracortical electrodes are 
showing promising results for restoring functionality to paralysis patients[2], [5], [42], 
[43]. Intracortical electrodes allow direct interfacing within the brain for single and multi-
unit recordings. A major problem in the field is the instability of viable recordings for long 
durations. Chronic (≥12 weeks) electrode failure, defined as a reduction in signal-to-noise 
ratio (SNR), continues to be documented across different electrode types in different 
animal species[12], [22]–[24], [52], [53]. In addition, animal-to-animal recording 
variability further confounds this problem[52], [54], [182]. Previous work has suggested 
that the severity and duration of chronic blood-brain barrier (BBB) breach may influence 
chronic recordings by contributing to local neurodegeneration[11], [12], [52], [183]. 
Chronic BBB degradation can result from a myriad of biological mechanisms. 
Initial damage by injury or disease recruits matrix metalloproteinases and reactive oxygen 
species to the site. This results in The BBB is composed of several cellular layers. 
Endothelial cells are connected by tight junction proteins, including occludins, claudins, 
and zona-occludins (ZOs) and adherens junctions, VE-cadherin[29], [81], [184]. 
Surrounding endothelial cells are pericytes, which aid in blood flow and vessel 
maintenance[29], [81], [82]. Pericytes are enclosed in basement membrane, which includes 
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laminin and collagen IV[29], [81]. Astrocyte endfeet, which are rich in aquaporin-4 (AQP-
4), directly connect the vasculature to the neurons within the brain[29], [83]. Each of these 
individual proteins and cells regulate the transport of macromolecules, cytokines, and 
leukocytes into the brain, and dysfunction at any level can lead to dysregulation of the 
BBB[29], [184]. 
With so many points of failure, it might be helpful to investigate the mechanisms 
by which electrode implantation induces BBB leakage. Previous work from the Capadona 
lab has focused on an anti-oxidant mechanism (curcumin[101] and resveratrol[102], [103]) 
for non-functional electrodes, but while both therapies impacted histologically markers at 
2 weeks, there was no effect at 16 weeks[101]–[103]. Kozai et al implanted functional 
electrodes in a general inflammation caspase-1 knockout model with improved single unit 
recordings[60]. Sawyer et al explored a CCR2 knockout for non-functional electrode 
implants and saw reduced neuroinflammation histology as well as changes in M1/M2 like 
expression, suggesting inhibition of pro-inflammatory monocyte recruitment[13]. Other 
work has focused on correlating histological data with functional recordings[12], [22], 
[52], [53]. The results have shown a negative correlation between IgG expression (a 
systemic macromolecule) and SNR at the electrode interface[12], [22], [52]. However, 
while IgG expression demonstrates BBB leakage, it provides no information on how the 
BBB has been breached.  
For this study, key mechanisms of BBB dysregulation at the mRNA level were 
explored following electrode implantation. Animal-to-animal recording variability was 
leveraged to perform correlations with mRNA expression to better elucidate mechanisms 
associated with electrode failure. To achieve this objective, functional microwire 
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electrodes were implanted into the rat barrel cortex acutely (for 1 week) and chronically 
(for 14 weeks). At each endpoint, mRNA was extracted for Fluidigm multi-plex qRT-PCR 
analysis. The calculated fold changes for each animal were compared to its functional 
recordings via a Pearson coefficient correlation. Neuroinflammation and markers for BBB 
integrity were investigated (see Table 5).  
1.12 Methods 
  Surgical preparation and electrode implantation 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Georgia Institute of Technology. Adult male Sprague Dawley 
rats (250 – 300 g) were implanted for 1 week (n = 5) or 14 weeks (n = 6). The implanted 
electrodes were polyimide coated tungsten microwires (Tucker-Davis Technologies, FL). 
The array had 16 electrodes arranged in a 2 x 8 pattern spaced 300 µm apart in the x-
direction and 500 µm apart in the y-direction (See Figure 13A). The electrodes were 50 
µm in diameter and 5 mm in length. All microwires were sterilized by ethylene oxide and 
degassed for 12 hours. Each rat was anesthetized with 2% isoflurane, and their head was 
shaved and sterilized with chlorohexidine and isopropanol. Each rat’s head was 
stereotaxtically positioned and a subcutaneous injection of lidocaine (Henry Schein, NY) 
was administered locally prior to incision. Following a midline incision, the periosteum 
was scraped away and etch gel (Henry Schein, NY) was applied to the skull. Holes for the 
anchoring screws were then drilled (2 anterior to bregma, 2 posterior to lambda, and 1 
opposite the craniotomy), and 5 screws were inserted (See Figure 13B). A 3 x 5 mm 
craniotomy was drilled at 1.5 mm posterior from bregma and 4 mm lateral from the midline 
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(See Figure 13B). The dura was retracted using a bent 25-gauge needle and bleeding was 
controlled using gel foam (Pfizer, NY) soaked with sterile saline. Grounding wires were 
wrapped around the anchoring screws prior to insertion. Each array was implanted at a 15-
degree angle to a depth of 1200 µm, targeting the IV cortical layer of the barrel cortex. 
Sterile 1.5% SeaKem agarose (Lonza, NJ) was applied above the craniotomy and UV 
curing dental cement (Henry Schein, NY) was used to secure the electrodes to the anchor 
screws and the skull. The incision was wound clipped and animals were injected 
intramuscularly with buprenorphine. Animals received daily subcutaneous injections of 
antibiotic, Baytril (Bayer, PA), for 2 weeks. 
  Electrophysiology and analysis 
 
Figure 13 – (A) Implantation of microwire array and electrode site map. (B) 
Representative image of barrel cortex craniotomy and anchoring/grounding 
screws. (C) Average waveforms and (D) PCA plot for sorted units. (E) Signal and 




Weekly recordings were collected with a 32-channel data-acquisition system 
(Plexon, TX). Signals were amplified at 1000 x gain, band-pass filtered at 500-5000 Hz 
and sampled at 40 kHz. Animals were anesthetized with ketamine/xylazine/acepromazine 
cocktail as isoflurane suppresses cortical firing in the barrel cortex. For each recording 
session, two files where recorded: 1) an evoked file in which the rat’s whiskers were 
deflected for ~1 minute, generating action potentials, and 2) a noise file in which no signals 
were evoked for 10 seconds. In Offline Sorter (Plexon, TX), the channels in the evoked 
files were thresholded at -4σ (standard orders of deviation) and units were sorted using K 
means automatic sorting (See Figure 13C-E). Units that had fewer than 100 action 
potentials were excluded. Spontaneous action potentials were removed from the noise file. 
Sorted files were then exported into Matlab and custom code was used to calculate the SNR 
by dividing the peak-to-peak voltage (Vp-p) by 2 times the standard deviation of noise 
(Equation 4)[151], [152]. 










A nested three-way ANOVA model was made to determine significant changes in 
time. As described in Equation 5, µ is the grand mean, τ is the effect of time with i as the 
time index, α is the inter-animal variability with j as the index of animals, β is inter-
electrode variability with k as the electrode index nested within j (animals), and ε is error 
for time, animals and electrodes. If the p-value was less than 0.05, a multiple comparison 
was run in Matlab. 
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Equation 5 𝒚𝒊,𝒋,𝒌 = 𝝁 + 𝝉𝒊 + 𝜶𝒋 + 𝜷𝒌(𝒋) + 𝜺𝒊,𝒋,𝒌 
𝒊 = 𝟏, … , 𝟏𝟒; 𝒋 = 𝟏, … , 𝟔;  𝒌 = 𝟏, … , 𝟏𝟔;  
  qRT-PCR and analysis 
At the designated time point, animals were transcardially perfused with sterile PBS 
(200 mL). The electrodes and headcap were removed and the brain was extracted. A 4-mm 
biopsy punch was taken at a depth of 2 mm around the electrode implant site. The biopsy 
punch was immediately frozen in liquid nitrogen and stored at -80 °C. Age matched naïve 
animals were sacrificed in the same manner as well and the 4-mm biopsy punch was 
removed from a depth of 2 mm at the same location in the brain. Total RNA was extracted 
using the RNeasy Plus Universal Kit (Qiagen, CA). RNA integrity was assessed with the 
Agilent Bioanalyzer using Agilent RNA 6000 Nano Kit (Agilent Technologies, CA) and 
purity was assessed with the Nanodrop 8000 Spectrophotometer (Thermo Fisher Scientific, 
MA). For all samples, RNA integrity numbers were above 7, 260/280 were above 1.8, and 
260/230 were above 1.0. cDNA was synthesized using the Fluidigm Reverse Transcription 
kit (#100-6298) (Fluidigm, CA). A 96 qRT-PCR assay using the Fluidigm Biomark HD 
(Fluidigm, CA) was run in triplicate for each sample using the Duke Center for Genomic 
and Computational Biology. The Delta Gene Assays (Fluidigm, CA) were designed using 
the D3 Assay Design (Fluidigm, CA), and the sequences are shown in the supplementary 
data. CT values were averaged together across triplicates. ΔCT values were calculated by 
subtracting the geometric mean of four housekeeping genes (GAPDH, HRPT, SDHA, 
RPL13A) from each CT value. ΔΔCT values were calculated by subtracting the arithmetic 
average of the naïve samples from the ΔCT values. All statistics were performed in the 
ΔΔCT space. Fold change was then calculated by taking the base 2 exponent of – ΔΔCT. 
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A Bonferroni sequential correction[185] was applied to a student’s t test to determine 
significance between 1 and 14 week microwire animals. 
  Correlation analysis 
To correlate the relation between average SNR and mRNA fold change, a Pearson 
correlation coefficient (r) was calculated in Matlab as well a p-value for each correlation. 
 
 
Figure 14 – Average SNRs (x axis is time in weeks and y axis is SNR) and SNR 
heatmaps (x axis is time in weeks, the y axis is electrode, and the z axis heatmap is 
SNR) for (A) C1, (B) C2, (C) C4, (D) C5, (E) C7, and (F) C8. The averaged (G) SNR, 
(H) standard deviation of noise, (I) peak-to-peak voltage, and (J) single units across 
animals (* p < 0.05 compared to week 1). 
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This was done for both the 1 week and the 14 week cohort. Briefly, electrode SNRs for 
each animal were averaged at each timepoint. The 14 week SNRs were compared with the 
mRNA extracted at 14 weeks for each animal. 
1.13 Results 
  Animal-to-animal variability in electrophysiology 
Weekly recordings were conducted in the barrel cortex. Rats were anesthetized, and 
whiskers were deflected to generate evoked potentials. SNRs were calculated for each 
electrode within each time point within each animal. Eight rats were implanted for the 
chronic time point, but two were removed from the study due to head cap failure (C3 and 
C6). Figure 14A-F shows the SNR plots for each individual animal. There was no 
significant change over time in SNR, Vp-p, or single units (Figure 14G,I,J). However, noise 
did significantly increase at 11 and 12 weeks (Figure 14H). In this study, variability in 
recording performance amongst animals was significant and was used to investigate 
possible correlation with underlying molecular differences studied by mRNA expression 
analysis. Briefly, Pearson correlation coefficients and p-values were calculated for each 
mRNA primer and the corresponding animal’s SNR. Pearson correlation coefficients were 
considered significant when the p-value ≤ 0.05. 
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Figure 15 – Representative images of 16 electrode microwire arrays at 1 week with * representing electrode location for (A) 
CD68, (B) GFAP, and (C) NeuN antibody staining (scale bar = 100 µm). Fold change comparison between 1 and 14 weeks for 
(D) NeuN, (E) GFAP, and (F) CD68 (* p < 0.05, student’s t-test, Bonferroni corrected). Each time point was compared to age-
matched naïve controls to calculate fold change. (G) Pearson correlation values for CD68, GFAP and CD68 (* p < 0.05). 
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 Neuroinflammation 
After each time point, mRNA was extracted from biopsied brain tissue and mRNA 
expression was calculated. Neuroinflammation markers were analyzed in this study. This 
included CD68 for activated microglia/macrophages, GFAP for astrocytes, and NeuN for 
neuronal nuclei (Figure 15A-C). There was a significant reduction of CD68 expression 
from 1 to 14 weeks and a significant increase of GFAP 1 to 14 weeks (p < 0.05) (Figure 
15E,F). No change was observed for NeuN expression (Figure 15D). At 14 weeks, the 
Pearson correlation coefficient was positively significant for both NeuN and GFAP (r = 
0.85, p < 0.05, and r = 0.85, p < 0.05, Figure 15G). As NeuN marks neuronal nuclei, the 
 
Figure 16 – Fold change comparisons between 1 and 14 weeks for M1-like pro-
inflammatory markers (A) CD32, (B) CD64, (C) CD80, (D) CD86, and (E) CCR7, 
and M2-like anti-inflammatory markers (F) CD206, (G) CD163, and (H) Arg-1. 
Each time point was compared to age-matched naïve controls to calculate fold 
change. Pearson correlations for (I) M1-like and (J) M2-like markers (* p < 0.05). 
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positive correlation with SNR is suggestive that SNR represents neuronal health and 
activity at the electrode interface.  
 Inflammation milieu 
Macrophages are a strong part of the wound healing and regeneration response. 
Markers for M1-like or pro-inflammatory response were analyzed and were upregulated at 
both 1 and 14 weeks (Figure 16A-F). However, there was no significant change over time. 
No significance was found for Pearson correlation coefficients for pro-inflammatory 
markers (Figure 16I). For M2-like markers or anti-inflammatory response, CD206 and 
CD163 had a significant positive Pearson correlation coefficient at 14 weeks (r = 0.84, r = 
0.89, p < 0.05, Figure 16J).  
 Vascular integrity/BBB breach status 
 
Figure 17 – Fold change comparisons between 1 and 14 weeks for tight junction 
proteins (A) cldn-5, (B) ocln, (C) and ZO-1, and other BBB markers (E) cdh-5, (F) 
PDGFR-β, (G) and AQP-4 (* p < 0.05, student’s t-test, Bonferroni corrected). Each 
time point was compared to age-matched naïve controls to calculate fold change. 
Pearson correlations for (D) tight junction protein markers and (H) other BBB 
markers (* p < 0.05). 
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Previous research has demonstrated the importance of BBB and vasculature to 
neuronal health. Common markers for BBB tight junctions were first observed. ZO-1 had 
a significant upregulation at 14 weeks compared to 1 week (Figure 17C). No other 
significant changes from 1 to 14 weeks were observed for claudin-5 (cldn5) or occludin 
(ocln) (Figure 17A,B). No significant Pearson coefficient correlation was found for cldn5, 
ocln, or ZO-1 at 14 weeks (Figure 17D). Additional BBB markers were next evaluated, 
including cell-to-cell junctions, VE-cadherin (cdh-5), pericytes (PDGFR-β), and astrocyte 
endfeet (Aqp-4). Aqp-4 was significantly upregulated at 14 weeks compared to 1 week 
(Figure 17G). Expression levels remained the same for cdh-5 and PDGFR- β (Figure 
17E,F). There was a significant positive Pearson correlation coefficient at 14 weeks for 
cdh-5 and PDGFR- β (r = 0.85, r = 0.89, p < 0.05, Figure 17H). However, no significant 
correlation was observed for Aqp-4.  
 Leukocyte recruitment and adhesion 
 
Figure 18 – Fold change comparisons between 1 and 14 weeks for endothelial 
adhesion markers (A) ACAM, (B) ICAM1, (C) ICAM2, (D) sel-e, (E) sel-p, (F) 
VCAM1, and pan-leukocyte marker (G) CD45 (* p < 0.05, student’s t-test, 
Bonferroni corrected). Each time point was compared to age-matched naïve 
controls to calculate fold change. (H) Pearson correlation for endothelial adhesion 
and pan-leukocyte markers (* p < 0.05). 
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A detrimental outcome of BBB leakage is the infiltration of leukocytes. This can 
be monitored by leukocyte cell markers and endothelial cell adhesion markers.  The fold 
change for the pan-leukocyte marker (CD45) was analyzed and expression significantly 
decreased at 14 weeks compared to 1 week (p < 0.05, Figure 18G). However, no 
significant Pearson correlation was observed with SNR (Figure 18H). A variety of 
adhesion markers were analyzed (ACAM, ICAM1, ICAM2, sel-e, sel-p, VCAM1, Figure 
18A-F). All were significantly upregulated at 14 weeks (except for ICAM2), suggesting 
increased leukocyte extravasation, but again, no significant Pearson correlation was found 
(Figure 18H). 
1.14 Discussion 
If BMIs are to be successful, the signal from the intracortical electrode (i.e. the 
input) must be able to reliably and robustly record for long durations (on the order of years). 
Preclinical work has demonstrated the inevitable failure of intracortical electrodes post 12 
weeks[12], [22]–[24], [52], [53] as well as animal-to-animal variability[52], [54], [182]. 
Previously, a relation between BBB integrity and electrode performance has been 
demonstrated,[12] and here these findings have been extended via an investigation of the 
underlying molecular mechanisms. Penetration and destruction of vessels during 
implantation may explain electrode recording variability per animal, and the importance of 
vascular integrity has been implicated in several studies in regards to neural health and 
electrodes[12], [52], [77], [168]. However, the direct mechanisms driving BBB 
dysregulation and electrode failure are not well understood. This data has shown a positive 
correlation between SNR and different components of the BBB, and this information could 
better inform therapeutic approaches for reduced electrode failure. 
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 Expression levels for common neuroinflammation markers were evaluated. As seen 
in Table 5 and Figure 15D,E, significant positive correlation was observed for NeuN and 
GFAP, but not for CD68. Previous electrode literature has suggested that the development 
of the astroglial scar at the electrode tissue interface is the primary cause for signal 
degeneration[25]. This attitude was pervasive through other neurodegenerative fields, 
however, this view has begun to change. The Sofroniew lab has demonstrated the 
importance of astrocyte support in a spinal cord injury model, and through knock-out 
Table 5 – Overview of significant Pearson correlation at 14 weeks for (A) 
neuroinflammation markers, (B) Blood-brain barrier markers, (C) leukocyte 
infiltration markers, and (D) inflammation markers.  
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models, when the astrocytic scar is ablated, axonal regeneration is in fact impaired[186]. 
McCreery et al conducted an analysis with Utah electrodes implanted in the cat 
sensorimotor cortex for almost a year. Histology was correlated with electrophysiology 
using the Pearson correlation, and a significant positive correlation was found for both 
NeuN and GFAP within 80 µm of the electrode for signal amplitudes at the experiment 
endpoint[53]. Our data corroborates McCreery’s findings, suggesting that presence of 
GFAP+ astrocytes is positively correlated with increased SNR. Therefore, developing 
treatment to improve astrocyte recruitment (as opposed to inhibiting astrocytes) may prove 
beneficial for chronic intracortical implants.  
To investigate the status of the BBB, tight junction protein expression was analyzed 
(Table 5, Figure 17A,B). Tight junctions are crucial to maintaining a healthy, intact BBB, 
and loss can lead to neurodegeneration[29], [187]–[192]. Interestingly, no significant 
correlations were observed for these tight junction expressions. Additional components of 
the BBB were then investigated, including AQP-4, cdh5, and PDGFR-β (Table 5, Figure 
17C,D). While there was a significant correlation with GFAP expression, there was no 
correlation with AQP-4, which is a common marker on astrocyte end-feet interacting with 
the BBB. VE-cadherin (cdh5) had a significant positive correlation with the SNR. VE-
cadherin is a cell-to-cell junction for endothelial cells, and the removal of VE-cadherin 
severely weakens the BBB[81], [193], [194]. Thus far, no work has been done confirming 
the impact of VE-cadherin loss on neurodegeneration. However, our work suggests the 
importance of VE-cadherin for functional recordings and may provide a potential 
therapeutic target. 
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The data also shows a significant positive correlation between PDGFR-β, a 
common pericyte receptor, and SNR (See Table 5, Figure 17C,D). Pericytes are critical 
to embryonic blood vessel development, vasculature maintenance, and angiogenesis. 
PDGFR-β and PDGF-BB crosstalk between pericytes and endothelial cells is key to 
angiogenesis[195], [196]. Pericytes also regulate blood flow by constricting and dilating 
the endothelial cells[82]. Evaluation of PDGFR-β knockout mice demonstrated that 
vascular integrity in the brain was significantly compromised and became more susceptible 
to macromolecule leakage[111]. The Zlokovic lab built upon this work with the PDGFR-
β knockout model showing that pericyte loss reduced cerebral blood flow and degraded 
BBB tight junction proteins. This resulted in neurodegeneration, and pericyte loss 
exacerbated amyloid-β clearance in Alzheimer’s disease models[87], [197], [198]. The 
results from this study thus corroborate previously published data describing the 
importance of pericytes in the neurovascular unit and might suggest the importance of 
maintaining pericyte health to improve performance for intracortical electrodes. 
A common cause/impact of BBB leakage is the increased expression of adhesion 
markers and leukocytes[33], [34], [84], [199]. Therefore, these markers were investigated 
in correlation with SNR (Table 5, Figure 18C,D). No significant correlation was found 
for leukocytes (CD45) or adhesion markers (ACAM, ICAM1, ICAM2, sel-e, sel-p, 
VCAM1). Elahy et al demonstrated that loss of BBB integrity and inflammation does occur 
in an aging model, but no leukocytes were recruited[200]. Others have shown that while 
leukocytes are recruited in different BBB leakage models, this cellular presence does not 
lead to neurodegeneration[201], [202]. Our data may suggest that leukocyte infiltration is 
not a primary cause for neurodegeneration in an electrode implant model. 
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The influence of M1-like and M2-like environments on neural health has been an 
area of study within the central and peripheral nervous systems[13], [146], [203]–[209]. 
With BBB breach following disease or injury, the influx of innate macrophages can 
influence the neurological outcomes[204], [207]. Common M1-like (CCR7, CD32, CD64, 
CD80, CD86) and M2-like (Arg-1, CD163, CD206) markers were evaluated to determine 
the relation between inflammation and SNR (Table 5, Figure 16). At 1 week, M1-like 
CD80 and M2-like CD206 were both significantly negatively correlated with SNR. At 14 
weeks, M2-like CD163 was significantly positively correlated with SNR. CD163 is a 
general receptor found on all subsets M2-like macrophages, while CD206 is specific for 
M2a and M2c which is responsible for tissue repair and pro-healing functions[146], [203]. 
The impact of M1-like and M2-like would need further work to better elucidate the impact 
and role of these mechanisms. 
Overall, this data showed significant positive correlation between SNR and GFAP, 
VE-cadherin and PDGFR-β. No significant correlations for leukocyte extravasation, 
inflammatory phenotypes, or tight junction expression were observed. This would suggest 
the importance of astrocytes (GFAP), adherens junctions (VE-cadherin), and pericytes 
(PDGFR- β) for maintaining chronic SNR. These data offer insight into potential molecular 
mechanisms to explore for improving chronic intracortical recordings.  
1.15 Conclusion  
The objective of this work was to better understand the molecular mechanisms 
influencing recording fidelity in electrode implant models. Previous work has suggested 
that BBB breach can influence chronic recordings. By embracing animal variability, 
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mRNA expression was correlated with SNR. Astrocytes, pericytes, and adherens junctions 
were identified as potential therapeutic targets to improve chronic intracortical recordings. 
Additional work with knock-out models and histological analysis is necessary to further 
validate the effect of these pathways. It is also important to remember that microwires were 
used for this study, and comparison to commonly used Michigan (research) and Utah 
(clinical) electrodes would be beneficial. This work provides direction for future studies 
and identification of BBB integrity markers that may influence and benefit chronic 
recordings in intracortical electrodes.   
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PERSPECTIVES AND FUTURE DIRECTIONS 
This thesis investigated biological mechanisms that targeted the blood-brain barrier 
in an intracortical electrode model and evaluated the impact on chronic 
electrophysiological recordings. In 0, a therapeutic strategy was applied to functional 
NeuroNexus probes targeting the inflammatory response and BBB breach via the 
CCL2/CCR2 pathway. CCR2-antagonism significantly reduced inflammation and BBB 
breach at 2 weeks. At 12 weeks, all CCR2-antagonist treated animals still had active 
electrodes, while only 1 out of the 5 control animals had active electrodes. A subtle but 
significant change was observed at the electrode-tissue interface. Animals treated with the 
CCR2-antagonist had significantly higher NeuN+ cells and EBA+ vasculature within 100 
µm of the electrode. In Error! Reference source not found., the objective was to identify 
dditional molecular pathway activated in the electrode implant model and correlate this 
data with functional electrophysiology. mRNA expression to implanted microwires was 
evaluated at 1 and 14 weeks with a focus on neuroinflammation, blood-brain barrier, 
leukocyte infiltration, and innate inflammation. SNR and mRNA expression were 
correlated at 14 weeks and significant positive correlation was found for markers of the 
BBB and M2-like inflammation. 
The significance of this work is the increased understanding of the biological 
mechanisms at play in an intracortical electrode implant model. Additionally, these 
mechanisms have been correlated with electrophysiology, assessing functionality. Future 
work includes developing a more detailed understanding of the CCL2/CCR2 pathway, as 
well as exploring the effects of PDGFR-β, MMP-9, and MMP-2 knock models on 
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electrophysiology. Alternatively, from a mechanical perspective, the presence of an 
external connector suggests that the meninges (a part of the BBB) may never close and 
remain chronically leaky. Exploring wireless technology and the impact of this device 
design in vivo will be crucial for closing the BBB and assessing effects on targeted 
biological mechanisms and electrophysiology. 
1.16 Biological mechanisms and metrics 
The focus of this thesis has been on the biological mechanisms that contribute to 
neurodegeneration at the electrode interface by targeting the blood-brain barrier. When 
evaluating intracortical electrodes, two biological phenomena occur: 1) acute injury and 2) 
chronic foreign body response. The chronic foreign body is less understood, and a small 
histological window has been used to identify microglia, astrocytes, and neurons at the 
electrode-tissue interface. More characterization studies are needed to better understand 
the mechanisms activated at these later timepoints. Additionally, expanding the breadth of 
metrics for classifying neurodegeneration and BBB breach will strengthen this analysis. 
 Characterization of mechanisms in the intracortical electrode implant model 
 For analyzing current and future mechanisms, mRNA and protein analysis 
(Western blots, proteomics) can help characterize the temporal response of the pathway of 
interest. Additionally, knock-out models can be used to further explore the importance of 
a gene in terms of healing and recovery. From this thesis, further exploration is needed for 
the CCL2/CCR2 mechanism. Another mechanism that emerged from Error! Reference 
ource not found. that would be interesting to evaluate is PDGFR-β. Finally, previous 
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intracortical electrode data suggested the importance of MMP-9 and MMP-2, both acutely 
and chronically, and future studies can be developed to study this mechanism. 
 CCR2, the BBB, and intracortical electrodes 
As a follow-up to the work completed in 0, it would be beneficial to develop a better 
understanding of a therapeutic window. At the start of this thesis, two schools of thought 
were discussed for treatment administration: 1) begin treatment immediately and cease at 
an acute timepoint or 2) begin treatment immediately and continue chronically; however, 
a third option has become apparent: 3) delay treatment until a determined chronic 
timepoint. Before testing the many different iterations of these options, it would be 
beneficial to analyze the mRNA and/or protein of CCL2 and CCR2 at different time points 
following implantation. From this information, a more informed injection strategy can be 
implemented.  
 PDGFR-β, the BBB, and intracortical electrodes 
PDGFR-β is a common marker on pericytes, which is part of the BBB. Research 
demonstrated that the absence of PDGFR-β significantly impacted the fidelity of the BBB 
and directly correlated with pericytes on the vasculature[210]. Pericyte loss has also been 
heavily implicated in Alzheimer’s disease, leading to BBB breach and 
neurodegeneration[87], [211]. The results from Error! Reference source not found. 
uggest that PDGFR-β is correlated with chronic electrode performance. It would be 
interesting to explore the role of PDGFR-β in terms of electrode implants and use a 
PDGFR-β KO model for initial data. As microwires have been shown to robustly record 
SNRs, implantation of microwires into the PDGFR-β KO model could be used as a rapid 
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failure model. The PDGFR-β KO model has been validated as having a leaky BBB. 
Tracking electrode performance with this model could be directly related to BBB breach 
at the endpoint. Also, electrophysiological and histological outcomes at 16 weeks in the 
PDGFR-β KO compared to the wild-type can demonstrate if PDGFR-β is an active 
mechanism in intracortical electrodes. 
 MMPs, the BBB, and intracortical electrodes 
Matrix-metalloproteinase-9 (MMP-9) is an enzyme that breaks down extracellular 
matrix (ECM) and tight junction proteins, which are part of the BBB[85]. MMP-9 has been 
heavily researched in the stroke community as upregulation has been associated with the 
intracranial hemorrhage[212], [213]. Acute inhibition of MMP-9 using a KO model[214] 
or specific inhibition[215] reduces infarct volume and improves behavioral outcome at 24 
hours following middle cerebral arterial occlusion (MCAO). Additionally, daily injection 
of a MMP-2/MMP-9 inhibitor for 6 days following MCAO improved neural survival[215]. 
Another study used a general MMP inhibitor starting at 7 days post-MCAO and 
administered daily until 14 days to observe the impact of delayed MMP inhibition. 
Interestingly, non-specific MMP inhibition increased the infarct size at 14 days[216]. This 
data would suggest sensitive and acute modulation (< 7 days) of MMP-9 is necessary to 
produce a reduced infarct and increase behavioral outcomes. 
For intracortical implants, an MMP-9 KO model was explored. While minimal 
differences were observed at 2 and 4 weeks, by 8 weeks, the MMP-9 KO had a significant 
upregulation of immune cells compared to the wild-type control[217]. MMP-9 mRNA 
expression was analyzed in Michigan and microwires implanted for 3 days and 16 weeks. 
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Microwires had significantly less MMP-9 expression at 3 days compared to Michigan and 
significantly higher expression at 16 weeks[12]. A beneficial experiment would be to 
analyzed MMP-9 protein concentrations at 0, 3 days and 1 week after Michigan electrode 
implantation to create a response profile (Michigan electrodes would be used since MMP-
9 was significantly upregulated at 3 days[12]). Based on this information, a MMP-2/MMP-
9 inhibitor (SB-3CT) can be injected following electrode implantation for 1 day or daily 
for either 3 or 7 days. Rats would then be euthanized at 2 weeks. If a significant result is 
observed, the significant injection time can be repeated for a 16 week timepoint. 
Electrophysiology and protein collection at 16 weeks can also be conducted. 
Table 6 – Histological markers and functional tests used to define 































The same electrode study found that MMP-2 was significantly upregulated in 
microwires at both 3 days and 16 weeks compared to Michigan electrodes[12]. Unlike 
MMP-9, MMP-2 has been shown to have a pro-healing response in stroke[218], 
atherosclerosis[219], and spinal cord injury[220]. Analyzing tissue response after daily 
injections of MMP-2 in a Michigan electrode implant model would be an interesting 
experiment. Alternatively, Michigan electrodes could be implanted in a MMP-2 KO model 
and chronic tissue and electrophysiological outcomes could be compared to wild-type 
controls, with the hypothesis that MMP-2 deletion would result in significantly worse 
outcomes. 
 Additional metrics for improved histological analysis 
Through this thesis, two questions kept emerging: 1) how to show 
neurodegeneration, and 2) how to show BBB breach. The histology toolkit of the 
Bellamkonda is strong. However, to delve more deeply into analyzing neurodegeneration 
from histology, switching away from immunofluorescence is necessary. For a more 
detailed understanding of the state of the BBB, increased magnification (to 40 or 100x) is 
needed to identify tight junction proteins. 
 Methodology for better identifying health of neural tissue 
Neurodegeneration is a nebuluous term; its definition varies based on the pathology 
that is being observed. The exact mechanistic details of neurodegeneration at the electrode-
tissue interface are not well-defined. The main analysis tool has been histology, specifically 
NeuN and FluoroJade C[9], [11], [12], [221], and electrophysiology for functional 
outcomes[2], [12], [22], [23], [54], [222]. Unfortunately, immunofluorescence can be 
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limiting for interpreting health of cells. Along with hematoxylin and eosin (H&E), paraffin-
embedded immunohistochemistry can provide this information. Common antibodies from 
other neural diseases could be helpful for studying intracortical electrodes. These 
antibodies for neurodegeneration are outlined in Table 6 and are categorized by pathology.  
Multiple sclerosis (MS) and spinal cord injury (SCI) have demyelination and 
damage to axonal tracts. For MS, demyelination is the main neurologic focus. Experimental 
allergic encephalomyelitis (EAE) is used as the MS pre-clinical model, and histological 
markers for demyelination include Luxol fast blue, toluidine blue, myelin basic protein 
(MBP), and myelin oligodendrocyte glycoprotein (MOG) [86], [112], [223]–[229], all of 
which can be counterstained with cresyl violet, a general stain for neurons[225]. For spinal 
cord injury, analyzing axonal health is key and toluidine blue, TUNEL, and retrograde 
tracing is used[230]–[232]. 
Stroke and traumatic brain injury (TBI) all have a massive injury that occurs in the 
CNS and results in a lesion with neural death. For stroke, identifying the ischemic region 
and the resulting neural death is the primary focus. This is done with 2,3,5-
triphenyltetrazolium chloride (TTC), a common stain for hypoxia, NeuN, cresyl violet, and 
fluorojade C[74], [233]–[239]. TBI results in a necrotic core, markers used for neural 
toxicity include NeuN, fluorojade, cresyl violet, Luxol fast blue, and TUNEL[240]–[243]. 
From this overview, exploring paraffin-embedding for intracortical electrode 
histology would be beneficial to expound upon neurodegeneration markers. To start, 
pathology found in H&E stains can provide information on the morphology of cells at the 
electrode-tissue interface. From this analysis, the health of the neurons, as well as 
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classification of astrocytes and microglia, can be analyzed. In addition, antibodies such as 
cresyl violet, toluidine blue, and Luxol fast blue could better elucidate the state of neural 
networks.  
 Methodology for better identifying the health of BBB 
Several tracers exist to assess the quality of the BBB. Endogenous markers are 
proteins from the plasma and include albumin, IgG, and fibrinogen[244]. Evans blue binds 
to albumin and has been used as an injected tracer for BBB breach for decades[244], [245]. 
A variety of fluorescently-labeled injectable tracers exists including FITC-albumin, 
Alexafluor-555 cadaverine, and dextran-tetramethylrhodamine[111], [211], [244], [246], 
as well as fluorescently labeled beads of various micro and nano sizes[247], [248]. The 
selection of the tracer depends on the objective, but overall, it is good to confirm 
endogenous histology with a macromolecule tracer. In this thesis, endogenous IgG and 
Evans Blue were used in histology. 
Non-invasive imaging provides great insight into BBB breach. However, the 
existence of the metallic implant makes imaging difficult. Magnetic resonance imaging 
(MRI) is a straight-forward tool for assessing brain injury and lesions[249]–[252], as well 
as BBB breach using gadolinium and albumin labeled with gadolinium as a contrast 
agent[253]–[256]. A study was conducted using MRI in an intracortical electrode model, 
but the metallic artifact completely blurred the electrode-tissue interface[12]. Another 
experiment used infrared imaging to assess BBB leakage using fluorescence molecular 
tomography (FMT), which was successful. Unfortunately, penetration of the dental cement 
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headcap is not possible with this modality, so only non-fixed electrodes can be 
evaluated[12]. 
To better assess the health of vasculature, images can be taken using a confocal or 
spinning disk microscope at 40X to 100X. From the convolved z-stacked images, vessel 
diameter and length can be counted[111]. At this resolution, antibodies for tight junction 
proteins (ZO-1, occludin, claudin) can be imaged and analyzed for coverage[142], [192]. 
Along with H&E, transmission electron microscopy is another method to view the 
morphology of blood vessels at a high resolution[111], [121], [247]. These techniques 
would yield more in depth data on the state of the BBB at the electrode interface. 
1.17 Next generation electrodes – wireless integration 
Wireless recording devices are the next frontier for intracortical electrodes[257]. 
Current clinical intracortical electrodes connect directly from the brain to the exterior of 
 
Figure 19 – Examples of anatomical placement for 1) standard fixed electrodes, 
and 2) trans-cranial, 3) trans-meninges, and 4) sub-meninges wireless electrodes. 
Blue is the electronics package, while black are the electrodes. 
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the body[2], [3], [16], [43]. Removing this direct hardware link is crucial to reduce 
infection and prevent hardware removal, which is a standard requirement for safety as these 
devices leave research and become available to the public. Additionally, the necessity of 
tethered cables in current electrode designs further exacerbates the biological response 
within the brain. Going wireless will reduce the device footprint within the body (and 
brain).  
 Biological benefits of a wireless design 
For wireless recordings, three types of modalities exist for positioning the 
electrodes in relation to the skull and meninges, which are shown in Figure 19: 2) trans-
cranial, 3) trans-meninges, and 4) sub-meninges. While the first iterations of wireless 
electrodes will be trans-cranial (circuitry resting on skull, covered by skin) and trans-
meninges (circuitry resting on the brain, covered by the meninges), a more integrative goal 
would be to further miniaturize electronics for implants that will rest in the sub-meninges 
space. With today’s fixed and tethered electrode design, the meninges is unable to 
completely close with electrodes protruding from the brain to the external connector and 
headcap. While remaining open, cells and proteins from the meninges may coalesce at the 
tissue-electrode interface. In fact, meningeal inflammation was been correlated with 
neuronal loss in MS[258]–[260]. Additionally, having the proximal end of the electrode 
dental cemented to the skull results in micromotion that has an adverse effect on both the 
electronics and the brain. Research has demonstrated that compared to fixed electrodes, 
there is a reduced immune response to electrodes that are not connected to the skull[179]–
[181]. Moving towards a free floating, functional intracortical electrode can be highly 
beneficial. 
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The problem with the trans-cranial design is that while it removes external wires, 
the electronics package is situated on top of the skull. This design still requires a tethered 
cable (that is burrowed through the skull) to the electrodes below (See device 2 in Figure 
19). With the tethered cable, the same issues that are present in the current electrode design 
will remain at the neural interface (i.e. micromotion and an open meninges)[22]. A good 
example has been demonstrated with the Utah electrodes in primate work, in which the 
meninges aggressively encapsulates electrodes, causing complete removal from the neural 
tissue[54]. The trans-meninges and sub-meninges designs address both problems. 
Therefore, for future wireless designs, signal penetration through the skull will be a 
requirement.  
When comparing the benefits of the trans-meninges vs the sub-meninges design, 
the key difference is the location of the electronics package. Ideally, for the trans-meninges 
device, the meninges will regrow on top of the device with minimal disturbance. However, 
the location of the electronics could irritate the meninges. Additionally, the electronics 
package can act as a fixed point and may still result in micromotion at the electrode-tissue 
interface. A significant reduction in immune response was demonstrated when single 
electrodes were implanted in the sub-meninges as opposed to the trans-meninges[261]. The 
immediate restriction with the sub-meninges device is the miniaturization of electronics. 
But with advancements in semi-conductor technology (and Moore’s Law), this will not be 
a restriction for long. 
 Power and data transmission strategies 
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Wireless power transmission is a fast expanding field and near field techniques fall 
into four categories: 1) capacitive coupling, 2) inductive coupling, 3) magneto dynamic 
coupling, and 4) magnetic resonant coupling[262]. For recording within the brain, several 
wireless devices have been published using inductive coupling [257], [263]–[265] and 
magnetic resonant coupling[266], [267]. Radio frequency is the preferred modality for data 
transmission for these devices. More recently, ultrasound as a data and power transmission 
media has been demonstrated using millimetre sized recording devices (termed ultrasonic 
neural dust) in the peripheral nerve[268]. The overall goal for the ultrasonic neural dust is 
to become a sub-meninges device for implantation within the brain. In summary, the 
technology exists, it is just a matter of miniaturizing and demonstrating proof-of-concept. 
 Non-functional studies evaluating micromotion and meninges repair 
While functional wireless electrodes are being developed, an important non-
functional study would be to compare the immune response of trans-cranial (fixed), trans-
meninges, and sub-meninges electrodes. While studies have been conducted[179], [261], 
the electrodes were only implanted for 4 weeks. It is critical to observe the immune 
response at a chronic 16 week time point to deduce the impact of micromotion and an 
unhealed meninges on chronic neural interfaces. This study would also evaluate the impact 
of the BBB, but from a device design viewpoint, as opposed to a pharmaceutical 
modulation aim. With this information, the design focus of future wireless electrodes can 
be adapted to best minimize trauma to the body. Additionally, when exploring biological 
mechanisms, including a floating electrode as a “negative control” may be valuable. 
1.18 EcOGs vs intracortical electrodes 
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There are currently three categories of recording electrodes for the brain: 1) non-
invasive electroencephalography (EEG), 2) extracortical electrocorticography (EcOG), 
and 3) invasive intracortical electrodes (See Figure 20A). Across these modalities, the 
main difference is the proximity of the electrode interface with the neural tissue. The more 
invasive the electrode, the better the signal resolution; however, the stability of the 
electrode decreases and the health risk to the patient increases. Unlike EEG (which is in 
contact with the scalp) and EcOG (which rests on the surface of the brain), intracortical 
electrodes directly penetrate the brain. The physical proximity of intracortical electrodes 
to neurons makes recording of single-unit activity feasible, while the other modalities rely 
on LFPs, as seen in Figure 20B[269]. 
Several clinical trials have been conducted with EcOG as theses electrodes are used 
in epilepsy patients to identify seizure loci[270]. EcOGs also have a less invasive surgery 
and easy post-experiment removal when compared to intracortical electrodes, allowing for 
short-term recording experiments from epilepsy patients[271]–[273]. Clinical trials have 
been conducted on paralyzed patients implanted with EcOGs controlling a prosthetic 
    
Figure 20 – (A) Types of cortical recording modalities [269]. (B) Types of signals 
and locations recorded in the brain [286]. 
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arm[273], [274]. In both studies, high gamma frequencies (70 – 200 Hz) offered the most 
accurate directional control.  
As mentioned previously, high gamma is the same physiological range of single 
and multi-unit spikes. The Brain Gate group is using high gamma and epsilon frequencies 
(in addition to spikes) as inputs for the neural decoder[3]. Additional work revealed no 
significant difference in prosthetic control accuracy between neural decoders using spikes 
versus those using high frequency LFPs[42]. In more recent pre-clinical tests of research 
EcOG arrays, the electrodes are able to distinguish action potentials from the subdural 
surface of the brain[275], [270].  
As of this moment, it is unclear whether intracortical electrodes or EcOGs are the 
superior recording device. However, as research continues, EcOGs are able to record more 
precisely in the frequency ranges used in clinical trials of intracortical electrodes. EcOGs 
also have the added benefit of immense surface area coverage with minimal tissue damage. 
No superior device has yet emerged, and it is important for researchers to consider both 
modalities when attempting to record from within the brain. 
1.19 Conclusion – clinical translation 
In clinical trials, recorded action potentials from implanted electrodes are the input 
for machine control. Since signal strength decreases over time, research to improve SNR 
reliability is necessary. Better understanding the biological cascades induced by implanting 
a foreign body may be one avenue to increase SNR strength. Through this work, a 
therapeutic modality (the CCR2/CCL2 pathway) was evaluated and tested in a functional 
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electrode model. Additionally, mRNA expression of BBB and anti-inflammatory markers 
were correlated with chronic in vivo recordings. 
For future work investigating the biological response, further characterization of 
the CCL2/CCR2 pathway is recommended to develop a stronger timeline for therapy 
administration. In addition, researching PDGFR-β, MMP-9 and MMP-2 pathways may 
provide further insight for the role of the BBB in the intracortical electrode model. To better 
assess the state of neurodegeneration, changing to non-fluorescent immunohistochemistry 
will allow the visualization of neural morphology and health. For the BBB, a closer view 
(40 to 100x) is needed to assess the morphology of blood vessels and analyzed the integrity 
of the tight junction proteins. 
As the field moves forward, it is important to look towards the wireless electrode. 
A design change may eliminate a large part of the immune response currently observed. 
By removing the external connector, the micromotion from a fixed implant is removed and 
the meninges can heal over the electrode. It would be interesting to explore this hypothesis 
in future work. Evaluation of this device design in vivo will further elucidate the impact of 




A.1  Imatinib as a BBB modulation strategy in functional Michigan electrodes 
A.1.1 Introduction 
Imatinib has shown efficacy in several neurodegenerative and injury models, 
including spinal cord injury[113], multiple sclerosis[112], [276], ALS[277], traumatic 
brain injury[278], and stroke[110], [279], [280]. Imatinib targets the vasculature by 
inhibiting platelet derived growth factor receptors (PDGFRs). The PDGF family (PDGF-
A, B, C, and D) has been shown to increase BBB leakiness in an intracerebral hemorrhage 
stroke model[110], [280]. Su et al showed that imatinib reduced infarct size and reduced 
the negative impact of tPA by inhibiting the PDGFR-α receptor in a stroke model[110]. As 
PDGFs are involved in angiogenesis, imatinib may be preventing angiogenesis 
immediately following trauma. Research has shown that imatinib application reduces 
vasculature leakiness through abl/arg inhibition which increases VE-cadherin 
expression[124], [125], [281]. The objective of this study was to use imatinib to seal the 
blood-brain barrier in an intracortical implant model and observe the impact on 
electrophysiology. 
A.1.2 Methods 
 Non-functional and functional Michigan electrodes were implanted into Sprague 
Dawley rats for 2 and 12 weeks. Research grade imatinib (Selleckchem, TX) was 
administered IP at a dose of 30 mg/kg. Imatinib is insoluble in saline and was dissolved in 




Figure 21 – An overview of the histology analyzed at 2 and 12 weeks. (A) For EBA+ 
vasculature, there was a significant difference at 2 weeks between treatment and 
control, and a significant increase in control at 12 weeks compared to control. (B) 
For ColIV+ vasculature, there was no significant difference. (C) For IgG, there 
was a significant difference at 2 weeks. (D) For Evans Blue, there was no 
significance at 12 weeks. (E) For NeuN+ cells, there was a significant difference at 
2 weeks between treatment and control, and a significant increase in control at 12 
weeks compared to control. (F) For GFAP, there was no significant difference (* 
p < 0.05). 
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sterile saline for a total of 10% DMSO. For the 12 week study, weekly electrophysiology 
was conducted. SNR was calculated from the recordings. At the conclusion of the 
experiment, rats were euthanized via perfusion. Brains were cryosectioned and 
immunofluorescence staining wasa conducted. Following microscopy, images were 
analyzed for intensity profiles, cell counts, and percentage of thresholded image. 
A.1.3 Results 
A.1.3.1 Histology of 2 and 12 week study (Imatinib 30 mg/kg) 
The antibodies listed in Table 3 were used for the histology for this experiment. At 
2 weeks, imatinib increased EBA+ vasculature, reduced IgG expression, and increased 
NeuN+ cells (Figure 21A,C,E, 4-way nested ANOVA). However, by 12 weeks, there was 
no significant difference between treatment and control. There was no difference for 








Weekly electrophysiological recordings were conducted until 12 weeks. As seen in 
Figure 22B, there was no significant difference in SNR between treatment and control. 
Additionally, there was no change in the percentage of animals with active electrodes 
compared to control (Figure 22A). In the imatinib group, the first rat stopped recording at 
week 7, while the other 2 failed at week 11. 
A.1.3.3 Imatinib effect on weight change 
An initial study using imatinib at a dosage of 60 mg/kg revealed that rats injected 
daily with imatinib were not gaining weight, and there was a significant difference 
compared to the control counterparts (Figure 23A). Following FDA guidelines[282], the 
dosage was reduced by half to 30 mg/kg. For the 2 week study, rats injected daily had 
normal weight gain (data not shown). Over 12 weeks, imatinib injected rats did start to gain 
less weight compared to controls, starting at 9 weeks (Figure 23B, 2-way ANOVA). 
A.1.4 Discussion 
 
Figure 23 – (A) Weight change over time of imatinib injected rats (60 mg/kg) 
compared to control (* p < 0.05). (B) Weight change over time of imatinib injected 
rats (30 mg/kg) compared to control (* p < 0.05). 
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Imatinib significantly changed the immune response at 2 weeks in a Michigan 
intracortical electrode implant model. However, at 12 weeks, there was no difference in 
electrophysiological or histological outcomes. Imatinib is PDGFR inhibitor and one 
concern using this pharmaceutical is the chronic effect. Inhibiting angiogenesis may be 
beneficial acutely, but the impact of preventing communication between pericytes and 
endothelial cells chronically is unknown. From the histological data, daily administration 
of imatinib may not worsen the immune response at the electrode interface when compared 
to controls. 
  
Figure 24 – Representative images of IgG (A) and CD45 (B) intensity for, as well 
as (C) IgG and (D) CD45 percentage area covered. 
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A1.4.1 Injected imatinib is more toxic than reported in literature 
It is important to acknowledge that the concentration of imatinib was reduced for 
the microwire experiment (from 60 mg/kg to 30 mg/kg). It was observed after the 2 week 
study that the imatinib-treated animals (60 mg/kg) did not gain weight (which is abnormal 
for young male rats). During perfusion, peritoneal adhesions on the liver were observed. A 
literature search revealed two papers which had reported similar findings. Han et al 2009 
 
Figure 25 – Representative images of (A) GFAP and (B) CD68 intensity for control 
and 4 week imatinib treatment. (C) IgG and (D) CD45 percentage area covered. 
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reported that db/db mice given IP injections of 50 – 75 mg/kg of imatinib had peritoneal 
adhesions and general weakness[283]. Wolf et al 2010 reported severe toxicity (and death) 
in C57BL/6 mice that received 200 mg/kg daily IP doses of imatinib. Mice that received 
50 mg/kg IP imatinib were sacrificed at 22 days due to local toxicity (lesions in the 
abdominal organs). However, in the same study, mice that received 400 mg/kg of imatinib 
orally displayed no symptoms[284]. When the toxicity of the 60 mg/kg IP dose was 
revealed, the dose for the rats was reduced to 30 mg/kg based on FDA 
recommendations[282]. The 60 mg/kg dosing was suggested for mice, but as rats have a 
lower metabolism (by 50%), the dosing was reduced by half. Initially, imatinib had no 
impact on weight gain. However, by 9 weeks, rats in the imatinib treatment had started to 
gain significantly less weight. 
A.1.5 Conclusion 
 
Figure 26 – Representative images of (A) NeuN intensity for control and 4 week 
imatinib treatment. (B) NeuN cell count and (C) SNR. 
 88 
At 2 weeks, imatinib appears to have reduced the immune response by several 
viable histological markers. However, the 12 week data shows no differences across 
electrophysiology or histology. Imatinib did not have any significant impact chronically in 
the intracortical electrode model.  
A.2 Imatinib as a BBB modulation strategy in functional microwires electrodes 
A.2.1 Results 
Contrary to the results observed in the 2 week Michigan electrode study, no 
significant difference was observed in IgG accumulation between the imatinib-treated and 
control animals (Figure 24a,b,e). CD45+ cells were also evaluated. Again no significant 
difference was seen (Figure 24c,d,f).  
A well-defined astrocyte scar was observed encapsulating the control microwires 
(Figure 25a). However, no difference was seen between the imatinib-treated and control 
animals in GFAP coverage (Figure 25a,b,e). Interestingly, at 4 weeks around microwires, 
CD68+ cells were observed at the electrode interface. When compared to the 2 week 
Michigan electrode data, CD68+ cells are no longer present at 2 weeks and onwards (which 
has been shown in the literature [11]). However, no difference was seen in CD68 
expression between the control and imatinib-treated animals (Figure 25c-f). 
Neuronal density was histological evaluated by counting NeuN+ cells in a 100 μm 
radius circle around the electrode. This analysis revealed no differences between the 
control and imatinib-treated group (Figure 26a-c). Signal-to-noise ratios were also 
calculated over the 4 week time course of the experiment. No significant differences were 
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observed either (Figure 26d). However, there was significant difference between time 
points, with the maximum SNRs occurring at 3 and 4 weeks. 
A.3 mRNA analysis at 2 weeks for Michigan probes comparing CCR2-antagonist 
After 2 weeks of implantation of Michigan electrodes, in which the treatment group 
received daily CCR2-antagonist injection, tissue was extracted. Total mRNA was 
extracted, and cDNA was amplified. mRNA primers for M1-like and M2-like phenotypes 
were selected from previous work (CD68, CCR7, CD80, CD163, CD206, Arg-1)[13]. A 
96-channel Fluidigm qRT-PCR was run, and fold change was calculated from the resulting 
CT values. No significant differences were found between treatment and control across the 
6 selected primers (Figure 27). 
 
Figure 27 – Fold change from qRT-PCR for (A) activated microglia/macrophages 
(CD68), (B,C) M1-like pro-inflammatory markers (CCR7, CD80), and (D-F) M2-
like anti-inflammatory markers (CD163, CD206, Arg-1). 
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A.4 TDT Microwires vs NeuroNexus Probes 
This thesis dealt with two common research intracortical probes, TDT microwires 
and NeuroNexus electrodes. Previous work from this lab reported to improved SNR 
strength and longevity of microwires compared to NeuroNexus probes. The same study 
noted that microwires had significantly less IgG accumulation at 16 weeks when compared 
to NeuroNexus electrodes, suggesting a correlation between BBB breach and 
electrophysiological performance[12]. Electrophysiology between Chapter 3 and Chapter 
4 was compared, and the same results were found where microwires outperformed 
NeuroNexus probes over 12 weeks (Figure 28A, B). 
  
 
Figure 28 – Comparison between microwire array and NeuroNexus for (A) SNR 
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